

Mohammad Amjad Kamal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7223049/publications.pdf>

Version: 2024-02-01

556
papers

13,531
citations

30047

54
h-index

54882

84
g-index

575
all docs

575
docs citations

575
times ranked

19941
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment. Saudi Journal of Biological Sciences, 2015, 22, 90-101.	1.8	486
2	Computer Aided Drug Design: Success and Limitations. Current Pharmaceutical Design, 2016, 22, 572-581.	0.9	281
3	Essential Oils: Extraction Techniques, Pharmaceutical And Therapeutic Potential - A Review. Current Drug Metabolism, 2018, 19, 1100-1110.	0.7	236
4	Nanotechnology-based approaches in anticancer research. International Journal of Nanomedicine, 2012, 7, 4391.	3.3	217
5	Status of Acetylcholinesterase and Butyrylcholinesterase in Alzheimer's Disease and Type 2 Diabetes Mellitus. CNS and Neurological Disorders - Drug Targets, 2014, 13, 1432-1439.	0.8	209
6	Phytol: A review of biomedical activities. Food and Chemical Toxicology, 2018, 121, 82-94.	1.8	198
7	Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy. Seminars in Cancer Biology, 2021, 69, 166-177.	4.3	197
8	Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic. Environmental Research, 2022, 209, 112816.	3.7	189
9	Flavonoids as acetylcholinesterase inhibitors: Current therapeutic standing and future prospects. Biomedicine and Pharmacotherapy, 2018, 101, 860-870.	2.5	184
10	Biomarkers for Alzheimer's Disease Diagnosis. Current Alzheimer Research, 2017, 14, 1149-1154.	0.7	180
11	Inflammatory Process in Alzheimer's and Parkinson's Diseases: Central Role of Cytokines. Current Pharmaceutical Design, 2016, 22, 541-548.	0.9	175
12	A Review on Nano-Antimicrobials: Metal Nanoparticles, Methods and Mechanisms. Current Drug Metabolism, 2017, 18, 120-128.	0.7	173
13	Risk of colorectal cancer in inflammatory bowel diseases. Seminars in Cancer Biology, 2020, 64, 51-60.	4.3	146
14	Polypharmacological Properties and Therapeutic Potential of Î²-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise. Current Pharmaceutical Design, 2016, 22, 3237-3264.	0.9	146
15	Protein Misfolding and Aggregation in Alzheimer's Disease and Type 2 Diabetes Mellitus. CNS and Neurological Disorders - Drug Targets, 2014, 13, 1280-1293.	0.8	138
16	Neuroinflammation in Alzheimer's Disease. Advances in Protein Chemistry and Structural Biology, 2017, 108, 33-57.	1.0	129
17	Flavonoids nanoparticles in cancer: Treatment, prevention and clinical prospects. Seminars in Cancer Biology, 2021, 69, 200-211.	4.3	129
18	Oxidative Stress Mediated Mitochondrial and Vascular Lesions as Markers in the Pathogenesis of Alzheimer Disease. Current Medicinal Chemistry, 2014, 21, 2208-2217.	1.2	127

#	ARTICLE	IF	CITATIONS
19	Andrographolide, a diterpene lactone from <i>Andrographis paniculata</i> and its therapeutic promises in cancer. <i>Cancer Letters</i> , 2018, 420, 129-145.	3.2	125
20	A Synopsis on the Role of Tyrosine Hydroxylase in Parkinson's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2012, 11, 395-409.	0.8	111
21	Nanotechnology-based inhalation treatments for lung cancer: state of the art. <i>Nanotechnology, Science and Applications</i> , 2015, 8, 55.	4.6	105
22	Role of Gut Microbiota in Obesity, Type 2 Diabetes and Alzheimer's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 305-311.	0.8	94
23	The Role of microRNAs in Alzheimer's Disease and Their Therapeutic Potentials. <i>Genes</i> , 2018, 9, 174.	1.0	90
24	Antiviral effects of probiotic metabolites on COVID-19. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 4175-4184.	2.0	89
25	Dietary Phytochemicals: Natural Swords Combating Inflammation and Oxidation-Mediated Degenerative Diseases. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-25.	1.9	88
26	Oxidative Stress and Antioxidant Potential of One Hundred Medicinal Plants. <i>Current Topics in Medicinal Chemistry</i> , 2017, 17, 1336-1370.	1.0	84
27	Enzyme targeting strategies for prevention and treatment of cancer: Implications for cancer therapy. <i>Seminars in Cancer Biology</i> , 2019, 56, 1-11.	4.3	81
28	A comprehensive review on biological properties of citrinin. <i>Food and Chemical Toxicology</i> , 2017, 110, 130-141.	1.8	78
29	The diabetic brain and cognition. <i>Journal of Neural Transmission</i> , 2017, 124, 1431-1454.	1.4	77
30	Peripheral Chemo-Cytokine Profiles in Alzheimers and Parkinsons Diseases. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009, 9, 1229-1241.	1.1	76
31	Analysis of post COVID-19 condition and its overlap with myalgic encephalomyelitis/chronic fatigue syndrome. <i>Journal of Advanced Research</i> , 2022, 40, 179-196.	4.4	75
32	Determination of sugars in honey by liquid chromatography. <i>Saudi Journal of Biological Sciences</i> , 2011, 18, 17-21.	1.8	74
33	Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise. <i>Current Pharmaceutical Design</i> , 2016, 22, 4341-4359.	0.9	73
34	Recent Updates in the Treatment of Neurodegenerative Disorders Using Natural Compounds. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-7.	0.5	71
35	Dietary flavonoids: Nano delivery and nanoparticles for cancer therapy. <i>Seminars in Cancer Biology</i> , 2021, 69, 150-165.	4.3	71
36	Experimental model for ELF-EMF exposure: Concern for human health. <i>Saudi Journal of Biological Sciences</i> , 2015, 22, 75-84.	1.8	68

#	ARTICLE	IF	CITATIONS
37	Neuroprotective Role of Steroidal Sex Hormones: An Overview. <i>CNS Neuroscience and Therapeutics</i> , 2016, 22, 342-350.	1.9	68
38	Anti-cancer Effects of Metformin: Recent Evidences for its Role in Prevention and Treatment of Cancer. <i>Current Drug Metabolism</i> , 2018, 19, 793-797.	0.7	68
39	Evidence and prospective of plant derived flavonoids as antiplatelet agents: Strong candidates to be drugs of future. <i>Food and Chemical Toxicology</i> , 2018, 119, 355-367.	1.8	66
40	Tau and mTOR: The Hotspots for Multifarious Diseases in Alzheimer's Development. <i>Frontiers in Neuroscience</i> , 2018, 12, 1017.	1.4	65
41	Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. <i>Scientific Reports</i> , 2019, 9, 5389.	1.6	64
42	Folate-conjugated nanovehicles: Strategies for cancer therapy. <i>Materials Science and Engineering C</i> , 2020, 107, 110341.	3.8	64
43	Prevalence of Headache in Patients With Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis of 14,275 Patients. <i>Frontiers in Neurology</i> , 2020, 11, 562634.	1.1	64
44	Correlation of Toll-like Receptor 4, Interleukin-18, Transaminases, and Uric Acid in Patients With Chronic Periodontitis and Healthy Adults. <i>Journal of Periodontology</i> , 2015, 86, 431-439.	1.7	63
45	Natural therapeutics and nutraceuticals for lung diseases: Traditional significance, phytochemistry, and pharmacology. <i>Biomedicine and Pharmacotherapy</i> , 2022, 150, 113041.	2.5	61
46	Kinetics of Human Serum Butyrylcholinesterase Inhibition by a Novel Experimental Alzheimer Therapeutic, Dihydrobenzodioxepine Cymserine. <i>Neurochemical Research</i> , 2008, 33, 745-753.	1.6	60
47	Updates on Managing Type 2 Diabetes Mellitus with Natural Products: Towards Antidiabetic Drug Development. <i>Current Medicinal Chemistry</i> , 2019, 25, 5395-5431.	1.2	60
48	Engineered nanoparticles for imaging and drug delivery in colorectal cancer. <i>Seminars in Cancer Biology</i> , 2021, 69, 293-306.	4.3	60
49	Kinetics of human acetylcholinesterase inhibition by the novel experimental alzheimer therapeutic agent, tolsesine. <i>Biochemical Pharmacology</i> , 2000, 60, 561-570.	2.0	59
50	Nanomedicine in treatment of breast cancer – A challenge to conventional therapy. <i>Seminars in Cancer Biology</i> , 2021, 69, 279-292.	4.3	59
51	Honokiol: A review of its pharmacological potential and therapeutic insights. <i>Phytomedicine</i> , 2021, 90, 153647.	2.3	59
52	Solid Matrix Based Lipidic Nanoparticles in Oral Cancer Chemotherapy: Applications and Pharmacokinetics. <i>Current Drug Metabolism</i> , 2015, 16, 633-644.	0.7	59
53	Neuronal Cellular Responses to Extremely Low Frequency Electromagnetic Field Exposure: Implications Regarding Oxidative Stress and Neurodegeneration. <i>PLoS ONE</i> , 2014, 9, e104973.	1.1	58
54	The role of epigenetics in personalized medicine: challenges and opportunities. <i>BMC Medical Genomics</i> , 2015, 8, S5.	0.7	58

#	ARTICLE	IF	CITATIONS
55	Alzheimer's disease and type 2 diabetes via chronic inflammatory mechanisms. Saudi Journal of Biological Sciences, 2015, 22, 4-13.	1.8	58
56	Prevalence and characteristics of fever in adult and paediatric patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis of 17515 patients. PLoS ONE, 2021, 16, e0249788.	1.1	58
57	Bile Salt Stabilized Vesicles (Bilosomes): A Novel Nano-Pharmaceutical Design for Oral Delivery of Proteins and Peptides. Current Pharmaceutical Design, 2017, 23, 1575-1588.	0.9	58
58	Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis. Journal of Neural Transmission, 2008, 115, 889-898.	1.4	57
59	Evaluation of Anti-Inflammatory Properties of Isoorientin Isolated from Tubers of <i>Pueraria tuberosa</i> . Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-10.	1.9	57
60	Neuroprotective Mechanisms Mediated by CDK5 Inhibition. Current Pharmaceutical Design, 2016, 22, 527-534.	0.9	57
61	Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective. Current Alzheimer Research, 2017, 14, 1164-1181.	0.7	57
62	miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease. Medicinal Chemistry, 2016, 12, 217-225.	0.7	57
63	Manuka Honey Exerts Antioxidant and Anti-Inflammatory Activities That Promote Healing of Acetic Acid-Induced Gastric Ulcer in Rats. Evidence-based Complementary and Alternative Medicine, 2017, 2017, 1-12.	0.5	56
64	A cross-talk between gut microbiome, salt and hypertension. Biomedicine and Pharmacotherapy, 2021, 134, 111156.	2.5	56
65	Cancer Chemoprevention by Polyphenols and Their Potential Application as Nanomedicine. Journal of Environmental Science and Health, Part C: Environmental Carcinogenesis and Ecotoxicology Reviews, 2013, 31, 67-98.	2.9	55
66	Conotoxins: Structure, Therapeutic Potential and Pharmacological Applications. Current Pharmaceutical Design, 2016, 22, 582-589.	0.9	54
67	Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective. Current Pharmaceutical Design, 2016, 22, 4360-4373.	0.9	53
68	Relationship between Inflammatory Mediators, A β Levels and ApoE Genotype in Alzheimer Disease. Current Alzheimer Research, 2012, 9, 447-457.	0.7	50
69	Link between Cancer and Alzheimer Disease via Oxidative Stress Induced by Nitric Oxide-Dependent Mitochondrial DNA Overproliferation and Deletion. Oxidative Medicine and Cellular Longevity, 2013, 2013, 1-19.	1.9	49
70	Reduction of post-prandial hyperglycemia by mulberry tea in type-2 diabetes patients. Saudi Journal of Biological Sciences, 2015, 22, 32-36.	1.8	48
71	Link Between Chronic Bacterial Inflammation and Alzheimer Disease. CNS and Neurological Disorders - Drug Targets, 2014, 13, 1140-1147.	0.8	48
72	Optimization protocol for the extraction of antioxidant components from <i>Origanum vulgare</i> leaves using response surface methodology. Saudi Journal of Biological Sciences, 2016, 23, 389-396.	1.8	47

#	ARTICLE	IF	CITATIONS
73	Bacteria From Marine Sponges: A Source of New Drugs. <i>Current Drug Metabolism</i> , 2017, 18, 11-15.	0.7	47
74	An Insight into the Therapeutic Potential of Major Coffee Components. <i>Current Drug Metabolism</i> , 2018, 19, 544-556.	0.7	47
75	Unique Medicinal Properties of <i>Withania somnifera</i> : Phytochemical Constituents and Protein Component. <i>Current Pharmaceutical Design</i> , 2016, 22, 535-540.	0.9	46
76	Role of Graphene Nano-Composites in Cancer Therapy: Theranostic Applications, Metabolic Fate and Toxicity Issues. <i>Current Drug Metabolism</i> , 2015, 16, 397-409.	0.7	46
77	Recent Advances in Drug Delivery of Polymeric Nano-Micelles. <i>Current Drug Metabolism</i> , 2017, 18, 16-29.	0.7	46
78	Micro-RNAs in the regulation of immune response against SARS CoV-2 and other viral infections. <i>Journal of Advanced Research</i> , 2021, 30, 133-145.	4.4	45
79	Selective Acetyl- and Butyrylcholinesterase Inhibitors Reduce Amyloid- β ; Ex Vivo Activation of Peripheral Chemo-cytokines From Alzheimer's Disease Subjects: Exploring the Cholinergic Anti-inflammatory Pathway. <i>Current Alzheimer Research</i> , 2014, 11, 608-622.	0.7	45
80	Establishing Genomic/Transcriptomic Links Between Alzheimer's Disease and Type 2 Diabetes Mellitus by Meta-Analysis Approach. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 501-516.	0.8	45
81	New possibilities in hepatocellular carcinoma treatment. <i>Anticancer Research</i> , 2014, 34, 1563-71.	0.5	45
82	Hepatoprotective Effects of <i>Silybum marianum</i> (Silymarin) and <i>Glycyrrhiza glabra</i> (Glycyrrhizin) in Combination: A Possible Synergy. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-9.	0.5	44
83	Effects of extremely low frequency electromagnetic field (ELF-EMF) on catalase, cytochrome P450 and nitric oxide synthase in erythro-leukemic cells. <i>Life Sciences</i> , 2015, 121, 117-123.	2.0	44
84	An overview on the current status of cancer nanomedicines. <i>Current Medical Research and Opinion</i> , 2018, 34, 911-921.	0.9	44
85	Invokana (Canagliflozin) as a Dual Inhibitor of Acetylcholinesterase and Sodium Glucose Co-Transporter 2: Advancement in Alzheimer's Disease- Diabetes Type 2 Linkage via an Enzoinformatics Study. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 447-451.	0.8	44
86	Kinetics of Human Erythrocyte Acetylcholinesterase Inhibition by a Novel Derivative of Physostigmine: Phenserine. <i>Biochemical and Biophysical Research Communications</i> , 1998, 248, 180-185.	1.0	43
87	Inhibition on the growth of human MDA-MB-231 breast cancer cells in vitro and tumor growth in a mouse xenograft model by Se-containing polysaccharides from <i>Pyraacantha fortuneana</i> . <i>Nutrition Research</i> , 2016, 36, 1243-1254.	1.3	43
88	Nanoencapsulated dietary polyphenols for cancer prevention and treatment: successes and challenges. <i>Nanomedicine</i> , 2020, 15, 1147-1162.	1.7	43
89	In Silico Analysis of Green Tea Polyphenols as Inhibitors of AChE and BChE Enzymes in Alzheimer's Disease Treatment. <i>CNS and Neurological Disorders - Drug Targets</i> , 2016, 15, 624-628.	0.8	43
90	New Delhi Metallo- β -Lactamase (NDM-1): An Updates. <i>Journal of Chemotherapy</i> , 2011, 23, 263-265.	0.7	42

#	ARTICLE	IF	CITATIONS
91	A Bayesian Model for the Prediction and Early Diagnosis of Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 77.	1.7	42
92	Effects of Honey on Oral Mucositis among Pediatric Cancer Patients Undergoing Chemo/Radiotherapy Treatment at King Abdulaziz University Hospital in Jeddah, Kingdom of Saudi Arabia. <i>Evidence-based Complementary and Alternative Medicine</i> , 2017, 2017, 1-7.	0.5	42
93	Pharmacological and Toxicological Profile of Harmane- $\hat{1}^2$ -Carboline Alkaloid: Friend or Foe. <i>Current Drug Metabolism</i> , 2017, 18, 853-857.	0.7	42
94	Nanotechnological based miRNA intervention in the therapeutic management of neuroblastoma. <i>Seminars in Cancer Biology</i> , 2021, 69, 100-108.	4.3	42
95	Middle East respiratory syndrome: pathogenesis and therapeutic developments. <i>Future Virology</i> , 2019, 14, 237-246.	0.9	41
96	SARS-CoV-2 M ^{pro} inhibitors: identification of anti-SARS-CoV-2 M ^{pro} compounds from FDA approved drugs. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 2769-2784.	2.0	41
97	A Possible Link of Gut Microbiota Alteration in Type 2 Diabetes and Alzheimer's Disease Pathogenicity: An Update. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 383-390.	0.8	41
98	Current Acetylcholinesterase-Inhibitors: A Neuroinformatics Perspective. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 391-401.	0.8	41
99	Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine. <i>Journal of Alzheimer's Disease</i> , 2006, 10, 43-51.	1.2	40
100	Alzheimer's Disease And Type 2 Diabetes: Exploring The Association To Obesity And Tyrosine Hydroxylase. <i>CNS and Neurological Disorders - Drug Targets</i> , 2012, 11, 482-489.	0.8	39
101	Commonalities in Biological Pathways, Genetics, and Cellular Mechanism between Alzheimer Disease and Other Neurodegenerative Diseases: An In Silico-Updated Overview. <i>Current Alzheimer Research</i> , 2017, 14, 1190-1197.	0.7	39
102	Current Update on Synopsis of miRNA Dysregulation in Neurological Disorders. <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 14, 492-501.	0.8	39
103	Clinical biomarkers in sickle cell disease. <i>Saudi Journal of Biological Sciences</i> , 2015, 22, 24-31.	1.8	38
104	Mitochondria as an Easy Target to Oxidative Stress Events in Parkinson's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2012, 11, 430-438.	0.8	38
105	The Role of Epigenetic Modifications in Human Cancers and the Use of Natural Compounds as Epidrugs: Mechanistic Pathways and Pharmacodynamic Actions. <i>Biomolecules</i> , 2022, 12, 367.	1.8	38
106	CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics. <i>Journal of Advanced Research</i> , 2022, 40, 207-221.	4.4	37
107	Preventive and Therapeutic Potentials of Anthocyanins in Diabetes and Associated Complications. <i>Current Medicinal Chemistry</i> , 2019, 25, 5347-5371.	1.2	37
108	Psychopharmacology of Attention-Deficit Hyperactivity Disorder: Effects and Side Effects. <i>Current Pharmaceutical Design</i> , 2016, 22, 590-594.	0.9	37

#	ARTICLE	IF	CITATIONS
109	Nanoparticles, Neurotoxicity and Neurodegenerative Diseases. <i>Current Drug Metabolism</i> , 2015, 16, 676-684.	0.7	37
110	Natural Products Combating Neurodegeneration: Parkinson's Disease. <i>Current Drug Metabolism</i> , 2017, 18, 50-61.	0.7	37
111	An overview on the correlation of neurological disorders with cardiovascular disease. <i>Saudi Journal of Biological Sciences</i> , 2015, 22, 19-23.	1.8	36
112	Protective effects of raspberry on the oxidative damage in HepG2 cells through Keap1/Nrf2-dependent signaling pathway. <i>Food and Chemical Toxicology</i> , 2019, 133, 110781.	1.8	36
113	Inflammation and Alzheimer's Disease: Mechanisms and Therapeutic Implications by Natural Products. <i>Mediators of Inflammation</i> , 2021, 2021, 1-21.	1.4	36
114	Molecular Linkages Between Diabetes and Alzheimer's Disease: Current Scenario and Future Prospects. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 290-298.	0.8	36
115	Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2006, 1760, 200-206.	1.1	35
116	Tumor Angiogenesis and VEGFR-2: Mechanism, Pathways and Current Biological Therapeutic Interventions. <i>Current Drug Metabolism</i> , 2021, 22, 50-59.	0.7	34
117	Risk factors for acquisition of extended spectrum beta lactamase producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> in North-Indian hospitals. <i>Saudi Journal of Biological Sciences</i> , 2015, 22, 37-41.	1.8	33
118	miRNAs in SARS-CoV 2: A Spoke in the Wheel of Pathogenesis. <i>Current Pharmaceutical Design</i> , 2021, 27, 1628-1641.	0.9	33
119	Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer. <i>Current Pharmaceutical Design</i> , 2016, 22, 2947-2959.	0.9	33
120	Recent Updates on the Association Between Alzheimer's Disease and Vascular Dementia. <i>Medicinal Chemistry</i> , 2016, 12, 226-237.	0.7	33
121	Chinese herbal extracts (SK0506) as a potential candidate for the therapy of the metabolic syndrome. <i>Clinical Science</i> , 2011, 120, 297-305.	1.8	32
122	Combination of selenium-enriched green tea polysaccharides and Huo-ji polysaccharides synergistically enhances antioxidant and immune activity in mice. <i>Journal of the Science of Food and Agriculture</i> , 2015, 95, 3211-3217.	1.7	32
123	Anthocyanins: Multi-Target Agents for Prevention and Therapy of Chronic Diseases. <i>Current Pharmaceutical Design</i> , 2018, 23, 6321-6346.	0.9	32
124	Design and Delivery of Therapeutic siRNAs: Application to MERS-Coronavirus. <i>Current Pharmaceutical Design</i> , 2018, 24, 62-77.	0.9	32
125	Kinetic analysis of the toxicological effect of tacrine (Cognex®) on human retinal acetylcholinesterase activity. <i>Toxicology</i> , 2000, 147, 33-39.	2.0	31
126	Gold nanoparticles: A plausible tool to combat neurological bacterial infections in humans. <i>Biomedicine and Pharmacotherapy</i> , 2018, 107, 7-18.	2.5	31

#	ARTICLE	IF	CITATIONS
127	Inhibition of human acetylcholinesterase by cyclophosphamide. <i>Toxicology</i> , 1995, 96, 1-6.	2.0	30
128	Nanoparticles as a Carrier System for Drug Delivery Across Blood Brain Barrier. <i>Current Drug Metabolism</i> , 2017, 18, 129-137.	0.7	30
129	Genetic risk factors in thrombotic primary antiphospholipid syndrome: A systematic review with bioinformatic analyses. <i>Autoimmunity Reviews</i> , 2018, 17, 226-243.	2.5	30
130	Biological Mechanisms Linking Alzheimer's Disease and Type-2 Diabetes Mellitus. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 1192-1201.	0.8	30
131	A critical transcription factor NF- κ B as a cancer therapeutic target and its inhibitors as cancer treatment options. <i>Current Medicinal Chemistry</i> , 2020, 27, 4117-4132.	1.2	30
132	Suppression of retinol-binding protein 4 with RNA oligonucleotide prevents high-fat diet-induced metabolic syndrome and non-alcoholic fatty liver disease in mice. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2011, 1811, 1045-1053.	1.2	29
133	Synopsis on the Linkage of Alzheimer's and Parkinson's Disease with Chronic Diseases. <i>CNS Neuroscience and Therapeutics</i> , 2015, 21, 1-7.	1.9	29
134	Antimutagenic Effects of Selenium-Enriched Polysaccharides from <i>Pyracantha fortuneana</i> through Suppression of Cytochrome P450 1A Subfamily in the Mouse Liver. <i>Molecules</i> , 2016, 21, 1731.	1.7	29
135	Multiple Targets for the Management of Alzheimer's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2016, 15, 1279-1289.	0.8	29
136	Small Molecules from Nature Targeting G-Protein Coupled Cannabinoid Receptors: Potential Leads for Drug Discovery and Development. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-26.	0.5	28
137	Evaluation of propolis, honey, and royal jelly in amelioration of peripheral blood leukocytes and lung inflammation in mouse conalbumin-induced asthma model. <i>Saudi Journal of Biological Sciences</i> , 2015, 22, 780-788.	1.8	28
138	Prevalence of multidrug resistant and extended spectrum beta-lactamase producing <i>Pseudomonas aeruginosa</i> in a tertiary care hospital. <i>Saudi Journal of Biological Sciences</i> , 2015, 22, 62-64.	1.8	28
139	The use of Azoles Containing Natural Products in Cancer Prevention and Treatment: An Overview. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018, 18, 6-14.	0.9	28
140	<i>Candida</i> identification: a journey from conventional to molecular methods in medical mycology. <i>World Journal of Microbiology and Biotechnology</i> , 2014, 30, 1437-1451.	1.7	27
141	Assessment of circulating biochemical markers and antioxidative status in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients. <i>Saudi Journal of Biological Sciences</i> , 2015, 22, 106-111.	1.8	27
142	Antibiotics: A Bibliometric Analysis of Top 100 Classics. <i>Antibiotics</i> , 2020, 9, 219.	1.5	27
143	Nanoparticles guided drug delivery and imaging in gastric cancer. <i>Seminars in Cancer Biology</i> , 2021, 69, 69-76.	4.3	27
144	Advances and Implications in Nanotechnology for Lung Cancer Management. <i>Current Drug Metabolism</i> , 2017, 18, 30-38.	0.7	27

#	ARTICLE	IF	CITATIONS
145	A global report on the dynamics of COVID-19 with quarantine and hospitalization: A fractional order model with non-local kernel. <i>Computational Biology and Chemistry</i> , 2022, 98, 107645.	1.1	27
146	Role of GTPases in the Regulation of Mitochondrial Dynamics in Alzheimer's Disease and CNS-Related Disorders. <i>Molecular Neurobiology</i> , 2019, 56, 4530-4538.	1.9	26
147	Alzheimer's Disease and Natural Products: Future Regimens Emerging from Nature. <i>Current Topics in Medicinal Chemistry</i> , 2017, 17, 1408-1428.	1.0	26
148	A Molecular Bridge: Connecting Type 2 Diabetes and Alzheimer's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 312-321.	0.8	26
149	The Role of Viruses in Neurodegenerative and Neurobehavioral Diseases. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 1213-1223.	0.8	26
150	Down Regulated Expression of Claudin-1 and Claudin-5 and Up Regulation of β -Catenin: Association with Human Glioma Progression. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 1413-1426.	0.8	26
151	Panacea seed "Nigella": A review focusing on regenerative effects for gastric ailments. <i>Saudi Journal of Biological Sciences</i> , 2016, 23, 542-553.	1.8	25
152	Structure-Based Identification of Natural Products as SARS-CoV-2 Mpro Antagonist from <i>Echinacea angustifolia</i> Using Computational Approaches. <i>Viruses</i> , 2021, 13, 305.	1.5	25
153	What is Blockchain Technology and its Significance in the Current Healthcare System? A Brief Insight. <i>Current Pharmaceutical Design</i> , 2019, 25, 1402-1408.	0.9	25
154	Antioxidant, Antimicrobial Activity and Medicinal Properties of <i>Grewia asiatica</i> L.. <i>Medicinal Chemistry</i> , 2016, 12, 211-216.	0.7	25
155	Natural Products for the Prevention and Control of the COVID-19 Pandemic: Sustainable Bioresources. <i>Frontiers in Pharmacology</i> , 2021, 12, 758159.	1.6	25
156	In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2018, 17, 54-68.	0.8	24
157	Horizons of nanotechnology applications in female specific cancers. <i>Seminars in Cancer Biology</i> , 2021, 69, 376-390.	4.3	24
158	Translational Shift of HSP90 as a Novel Therapeutic Target from Cancer to Neurodegenerative Disorders: An Emerging Trend in the Cure of Alzheimer's and Parkinson's Diseases. <i>Current Drug Metabolism</i> , 2017, 18, 868-876.	0.7	24
159	Advanced Glycation End Products (AGEs), Glutathione and Breast Cancer: Factors, Mechanism and Therapeutic Interventions. <i>Current Drug Metabolism</i> , 2019, 20, 65-71.	0.7	24
160	Linking Alzheimer's Disease and Type 2 Diabetes Mellitus via Aberrant Insulin Signaling and Inflammation. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 338-346.	0.8	24
161	Do Folate, Vitamins B6 and B12 Play a Role in the Pathogenesis of Migraine? The Role of Pharmacoepigenomics. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 828-835.	0.8	24
162	Small molecule tyrosine kinase inhibitors and pancreatic cancer: Trials and troubles. <i>Seminars in Cancer Biology</i> , 2019, 56, 149-167.	4.3	23

#	ARTICLE	IF	CITATIONS
163	An Overview on Global Trends in Nanotechnological Approaches for Alzheimer Therapy. <i>Current Drug Metabolism</i> , 2015, 16, 719-727.	0.7	23
164	Synthesis of the Alzheimer Drug Posiphen into its Primary Metabolic Products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their Inhibition of Amyloid Precursor Protein, α -Synuclein Synthesis, Interleukin-1β Release, and Cholinergic Action.. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2013, 12, 117-128.	1.1	23
165	Proteomics Approaches to Understand Linkage Between Alzheimer’s Disease and Type 2 Diabetes Mellitus. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 213-225.	0.8	23
166	Role of Nanomedicines in Delivery of Anti-Acetylcholinesterase Compounds to the Brain in Alzheimer’s Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 1315-1324.	0.8	23
167	Improved efficiency and stability of secnidazole â“ An ideal delivery system. <i>Saudi Journal of Biological Sciences</i> , 2015, 22, 42-49.	1.8	22
168	Integrated Pathways of COX-2 and mTOR: Roles in Cell Sensing and Alzheimer’s Disease. <i>Frontiers in Neuroscience</i> , 2020, 14, 693.	1.4	22
169	A CBCT Based Three-Dimensional Assessment of Mandibular Posterior Region for Evaluating the Possibility of Bypassing the Inferior Alveolar Nerve While Placing Dental Implants. <i>Diagnostics</i> , 2020, 10, 406.	1.3	22
170	Elucidating Treatment of Alzheimer's Disease via Different Receptors. <i>Current Topics in Medicinal Chemistry</i> , 2017, 17, 1400-1407.	1.0	22
171	Fighting Alzheimer’s Disease and Type 2 Diabetes: Pathological links and Treatment Strategies. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 271-282.	0.8	22
172	Reduction in CD16/CD56 and CD16/CD3/CD56 Natural Killer Cells in Coronary Artery Disease. <i>Immunological Investigations</i> , 2017, 46, 526-535.	1.0	21
173	A Synopsis of Nano-Technological Approaches Toward Anti-Epilepsy Therapy: Present and Future Research Implications. <i>Current Drug Metabolism</i> , 2015, 16, 336-345.	0.7	21
174	Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease. <i>Current Drug Metabolism</i> , 2017, 18, 842-852.	0.7	21
175	C-Peptide and its Correlation to Parameters of Insulin Resistance in the Metabolic Syndrome. <i>CNS and Neurological Disorders - Drug Targets</i> , 2011, 10, 921-927.	0.8	21
176	How Do Periodontal Infections Affect the Onset and Progression of Alzheimer’s Disease?. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 460-466.	0.8	21
177	Identification of Potent Caspase-3 Inhibitors for Treatment of Multi- Neurodegenerative Diseases Using Pharmacophore Modeling and Docking Approaches. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 1346-1353.	0.8	21
178	Targeting BuChE-inflammatory Pathway by SK0506 to Manage Type 2 Diabetes and Alzheimer Disease. <i>Neurochemical Research</i> , 2009, 34, 2163-2169.	1.6	20
179	Managing the Combination of Nonalcoholic Fatty Liver Disease and Metabolic Syndrome with Chinese Herbal Extracts in High-Fat-Diet Fed Rats. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-10.	0.5	20
180	Development of Cotton leaf curl virus resistant transgenic cotton using antisense ÆYC1 gene. <i>Saudi Journal of Biological Sciences</i> , 2016, 23, 358-362.	1.8	20

#	ARTICLE	IF	CITATIONS
181	Assessment of genetic diversity in IL-6 and RANTES promoters and their level in Saudi coronary artery disease patients. <i>Journal of Clinical Laboratory Analysis</i> , 2017, 31, e22092.	0.9	20
182	Probiotics: Supplements, Food, Pharmaceutical Industry. , 2018, , 15-25.		20
183	Neural Stem Cell-Based Therapies and Glioblastoma Management: Current Evidence and Clinical Challenges. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2258.	1.8	20
184	Mechanistic insights into the Japanese encephalitis virus RNA dependent RNA polymerase protein inhibition by bioflavonoids from <i>Azadirachta indica</i> . <i>Scientific Reports</i> , 2021, 11, 18125.	1.6	20
185	Role of anti-diabetic drugs as therapeutic agents in Alzheimer's disease. <i>EXCLI Journal</i> , 2015, 14, 684-96.	0.5	20
186	Current Updates on Therapeutic Advances in the Management of Cardiovascular Diseases. <i>Current Pharmaceutical Design</i> , 2016, 22, 566-571.	0.9	20
187	Natural Products: A Rich Source of Antiviral Drug Lead Candidates for the Management of COVID-19. <i>Current Pharmaceutical Design</i> , 2021, 27, 3526-3550.	0.9	20
188	Applications of Nanotechnology in Diagnostics and Therapeutics of Alzheimer's and Parkinson's Disease. <i>Current Drug Metabolism</i> , 2015, 16, 705-712.	0.7	20
189	A Current Perspective on the Inhibition of Cholinesterase by Natural and Synthetic Inhibitors. <i>Current Drug Metabolism</i> , 2017, 18, 96-111.	0.7	20
190	Recent Development and Future Prospects of Plant-Based Vaccines. <i>Current Drug Metabolism</i> , 2017, 18, 831-841.	0.7	20
191	Alzheimer's Disease and Autistic Spectrum Disorder: Is there any Association?. <i>CNS and Neurological Disorders - Drug Targets</i> , 2016, 15, 390-402.	0.8	20
192	Neopterin: An immune biomarker of coronary artery disease and its association with other <sc>CAD</sc> markers. <i>IUBMB Life</i> , 2015, 67, 453-459.	1.5	19
193	Clinical Review of COVID-19; Pathogenesis, Diagnosis, and Management. <i>Current Pharmaceutical Design</i> , 2021, 27, 4232-4244.	0.9	19
194	Molecular Interaction of Acetylcholinesterase with Carnosic Acid Derivatives: A Neuroinformatics Study. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 440-446.	0.8	19
195	An Association of Virus Infection with Type 2 Diabetes and Alzheimer's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 429-439.	0.8	19
196	An Overview on the Role of α -Synuclein in Experimental Models of Parkinson's Disease from Pathogenesis to Therapeutics. <i>CNS and Neurological Disorders - Drug Targets</i> , 2016, 15, 1240-1252.	0.8	19
197	Bacterial Nanocellulose based Wound Dressings: Current and Future Prospects. <i>Current Pharmaceutical Design</i> , 2022, 28, 570-580.	0.9	19
198	Expression Profiling of Cytokine, Cholinergic Markers, and Amyloid- β Deposition in the APPSWE/PS1dE9 Mouse Model of Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 467-476.	1.2	18

#	ARTICLE	IF	CITATIONS
199	Persons with Co-Existing Neurological Disorders: Risk Analysis, Considerations and Management in COVID-19 Pandemic. <i>CNS and Neurological Disorders - Drug Targets</i> , 2022, 21, 228-234.	0.8	18
200	COVID-19 Outbreak and Emerging Management through Pharmaceutical Therapeutic Strategy. <i>Current Pharmaceutical Design</i> , 2020, 26, 5224-5240.	0.9	18
201	Phage Display Technique: A Novel Medicinal Approach to Overcome Antibiotic Resistance by Using Peptide-Based Inhibitors Against β -Lactamases. <i>Current Drug Metabolism</i> , 2017, 18, 90-95.	0.7	18
202	Non-coding RNAs in Lung Cancer Chemoresistance. <i>Current Drug Metabolism</i> , 2020, 20, 1023-1032.	0.7	18
203	Implication of Gut Microbiota in Human Health. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 1325-1333.	0.8	18
204	The preparation and kinetic properties of multiple forms of chicken brain acetylcholinesterase. <i>Cell Biochemistry and Function</i> , 1994, 12, 29-35.	1.4	17
205	Assessment of the role of general, biochemical and family history characteristics in kidney stone formation. <i>Saudi Journal of Biological Sciences</i> , 2015, 22, 65-68.	1.8	17
206	Metabolic regulation in HPV associated head and neck squamous cell carcinoma. <i>Life Sciences</i> , 2020, 258, 118236.	2.0	17
207	A deep neural network-based approach for prediction of mutagenicity of compounds. <i>Environmental Science and Pollution Research</i> , 2021, 28, 47641-47650.	2.7	17
208	Multi-Omics Approach in the Identification of Potential Therapeutic Biomolecule for COVID-19. <i>Frontiers in Pharmacology</i> , 2021, 12, 652335.	1.6	17
209	Association of Metronidazole with Cancer: A Potential Risk Factor or Inconsistent Deductions?. <i>Current Drug Metabolism</i> , 2018, 19, 902-909.	0.7	17
210	HTLV-1 Associated Neurological Disorders. <i>Current Topics in Medicinal Chemistry</i> , 2017, 17, 1320-1330.	1.0	17
211	Effects of Polysaccharides from Selenium-enriched <i>Pyracantha fortuneana</i> on Mice Liver Injury. <i>Medicinal Chemistry</i> , 2015, 11, 780-788.	0.7	17
212	Inhibition of Proliferation and Induction of Apoptosis by Thymoquinone via Modulation of TGF Family, p53, p21 and Bcl-2 in Leukemic Cells. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018, 18, 210-215.	0.9	17
213	Alzheimer's and Type 2 Diabetes Treatment via Common Enzyme Targeting. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 299-304.	0.8	17
214	Molecular Interaction of Human Brain Acetylcholinesterase with a Natural Inhibitor Huperzine-B: An Enoinformatics Approach. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 487-490.	0.8	17
215	Transcriptomics Study of Neurodegenerative Disease: Emphasis on Synaptic Dysfunction Mechanism in Alzheimer's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 1202-1212.	0.8	17
216	Telomeric Repeat Containing RNA (TERRA): Aging and Cancer. <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 14, 936-946.	0.8	17

#	ARTICLE	IF	CITATIONS
217	Natural Product-Based Studies for the Management of Castration-Resistant Prostate Cancer: Computational to Clinical Studies. <i>Frontiers in Pharmacology</i> , 2021, 12, 732266.	1.6	17
218	Diallyl disulfide and diallyl trisulfide in garlic as novel therapeutic agents to overcome drug resistance in breast cancer. <i>Journal of Pharmaceutical Analysis</i> , 2022, 12, 221-231.	2.4	17
219	Inhibition of Caspase 3 and Caspase 9 Mediated Apoptosis: A Multimodal Therapeutic Target in Traumatic Brain Injury. <i>Current Neuropharmacology</i> , 2023, 21, 1001-1012.	1.4	17
220	DeePred-BBB: A Blood Brain Barrier Permeability Prediction Model With Improved Accuracy. <i>Frontiers in Neuroscience</i> , 2022, 16, 858126.	1.4	17
221	Acetylcholinesterase from desert Cobra (<i>Walterinnesia aegyptia</i>) venom: Optimization and kinetics study. <i>Molecular and Cellular Biochemistry</i> , 1995, 151, 21-26.	1.4	16
222	Molecular Docking Studies Reveal Rhein from rhubarb (<i>Rheum rhabarbarum</i>) as a Putative Inhibitor of ATP-binding Cassette Super-family G member 2. <i>Medicinal Chemistry</i> , 2021, 17, 273-288.	0.7	16
223	Prevention Knowledge and Its Practice Towards COVID-19 Among General Population of Saudi Arabia: A Gender-based Perspective. <i>Current Pharmaceutical Design</i> , 2021, 27, 1642-1648.	0.9	16
224	LPS/TLR4 Pathways in Breast Cancer: Insights into Cell Signalling. <i>Current Medicinal Chemistry</i> , 2022, 29, 2274-2289.	1.2	16
225	Understanding the role of potential pathways and its components including hypoxia and immune system in case of oral cancer. <i>Scientific Reports</i> , 2021, 11, 19576.	1.6	16
226	Alkaloids: An Emerging Antibacterial Modality Against Methicillin Resistant <i>Staphylococcus aureus</i> . <i>Current Pharmaceutical Design</i> , 2016, 22, 4420-4429.	0.9	16
227	Single Probiotic versus Multiple Probiotics - A Debate On Current Scenario for Alleviating Health Benefits. <i>Current Pharmaceutical Design</i> , 2019, 24, 4150-4153.	0.9	16
228	Can Wogonin be Used in Controlling Diabetic Cardiomyopathy?. <i>Current Pharmaceutical Design</i> , 2019, 25, 2171-2177.	0.9	16
229	Tubulin Proteins in Cancer Resistance: A Review. <i>Current Drug Metabolism</i> , 2020, 21, 178-185.	0.7	16
230	Infectious Agents and Neurodegenerative Diseases: Exploring the Links. <i>Current Topics in Medicinal Chemistry</i> , 2017, 17, 1390-1399.	1.0	16
231	A Neuroinformatics Study Describing Molecular Interaction of Cisplatin with Acetylcholinesterase: A Plausible Cause for Anticancer Drug Induced Neurotoxicity. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 265-270.	0.8	16
232	Diabetes of the Brain: Computational Approaches and Interventional Strategies. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 408-417.	0.8	16
233	Prediction of Comparative Inhibition Efficiency for a Novel Natural Ligand, Galangin Against Human Brain Acetylcholinesterase, Butyrylcholinesterase and 5-Lipoxygenase: A Neuroinformatics Study. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 452-459.	0.8	16
234	Humanin: A Possible Linkage Between Alzheimer's Disease and Type 2 Diabetes. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 543-552.	0.8	16

#	ARTICLE	IF	CITATIONS
235	Interaction of Human Brain Acetylcholinesterase with Cyclophosphamide: A Molecular Modeling and Docking Study. <i>CNS and Neurological Disorders - Drug Targets</i> , 2011, 10, 845-848.	0.8	15
236	Observations on the expression of human papillomavirus major capsid protein in HeLa cells. <i>Cancer Cell International</i> , 2015, 15, 53.	1.8	15
237	Lactoperoxidase immobilization on silver nanoparticles enhances its antimicrobial activity. <i>Journal of Dairy Research</i> , 2018, 85, 460-464.	0.7	15
238	Zika Virus Targeting by Screening Inhibitors against NS2B/NS3 Protease. <i>BioMed Research International</i> , 2019, 2019, 1-11.	0.9	15
239	Characterization and Antimicrobial Susceptibility of Pathogens Associated with Periodontal Abscess. <i>Antibiotics</i> , 2020, 9, 654.	1.5	15
240	Diabetes Mellitus and Male Aging: Pharmacotherapeutics and Clinical Implications. <i>Current Pharmaceutical Design</i> , 2017, 23, 4475-4483.	0.9	15
241	Wogonin Alleviates Hyperglycemia Through Increased Glucose Entry into Cells Via AKT/GLUT4 Pathway. <i>Current Pharmaceutical Design</i> , 2019, 25, 2602-2606.	0.9	15
242	Multiple Risk Factors: A Challenge in the Management of Autism. <i>Current Pharmaceutical Design</i> , 2020, 26, 743-754.	0.9	15
243	Topical Discoveries on Multi-Target Approach to Manage Alzheimer's Disease. <i>Current Drug Metabolism</i> , 2018, 19, 704-713.	0.7	15
244	A Nanotechnological Approach to the Management of Alzheimer Disease and Type 2 Diabetes. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 478-486.	0.8	15
245	Current View from Alzheimer Disease to Type 2 Diabetes Mellitus. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 533-542.	0.8	15
246	Inhibition of Butyrylcholinesterase with Fluorobenzylcysteine, An Experimental Alzheimer's Drug Candidate: Validation of Enzoinformatics Results by Classical and Innovative Enzyme Kinetic Analyses. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017, 16, 820-827.	0.8	15
247	Association of Oxidative Stress with Neurological Disorders. <i>Current Neuropharmacology</i> , 2022, 20, 1046-1072.	1.4	15
248	mTOR Targeted Cancer Chemoprevention by Flavonoids. <i>Current Medicinal Chemistry</i> , 2021, 28, 8068-8082.	1.2	15
249	Purification and characterization of acetylcholinesterase from desert cobra (<i>Walterinnesia aegyptia</i>) venom. <i>Biochimie</i> , 1996, 78, 46-50.	1.3	14
250	Nanoneurotoxicity to Nanoneuroprotection Using Biological and Computational Approaches. <i>Journal of Environmental Science and Health, Part C: Environmental Carcinogenesis and Ecotoxicology Reviews</i> , 2013, 31, 256-284.	2.9	14
251	Genetic variability of Cotton leaf curl betasatellite in Northern India. <i>Saudi Journal of Biological Sciences</i> , 2014, 21, 626-631.	1.8	14
252	Assessment of IL-18 Serum Level and Its Promoter Polymorphisms in the Saudi Coronary Artery Disease (CAD) Patients. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 1849-1854.	1.2	14

#	ARTICLE	IF	CITATIONS
253	Editorial: The Alzheimer's Disease Challenge. <i>Frontiers in Neuroscience</i> , 2019, 13, 768.	1.4	14
254	Melatonin and Sleep Disturbances in Alzheimer's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2021, 20, 736-754.	0.8	14
255	Synopsis on Management Strategies for Neurodegenerative Disorders: Challenges from Bench to Bedside in Successful Drug Discovery and Development. <i>Current Topics in Medicinal Chemistry</i> , 2017, 17, 1371-1378.	1.0	14
256	A Brief Overview of Tyrosine Hydroxylase and α -Synuclein in the Parkinsonian Brain. <i>CNS and Neurological Disorders - Drug Targets</i> , 2012, 11, 456-462.	0.8	14
257	Alzheimer Disease and Type 2 Diabetes Mellitus: The Link to Tyrosine Hydroxylase and Probable Nutritional Strategies. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 467-477.	0.8	14
258	Aptiom (Eslicarbazepine Acetate) as a Dual Inhibitor of γ -Secretase and Voltage-Gated Sodium Channel: Advancement in Alzheimer's Disease- Epilepsy Linkage via an Enzoinformatics Study. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 1258-1262.	0.8	14
259	"Non-Criteria" Neurologic Manifestations of Antiphospholipid Syndrome: A Hidden Kingdom to be Discovered. <i>CNS and Neurological Disorders - Drug Targets</i> , 2016, 15, 1253-1265.	0.8	14
260	Prospective Function of Different Antioxidant Containing Natural Products in the Treatment of Neurodegenerative Diseases. <i>CNS and Neurological Disorders - Drug Targets</i> , 2021, 20, 694-703.	0.8	14
261	Estimation of BTEX in groundwater by using gas chromatography-mass spectrometry. <i>Saudi Journal of Biological Sciences</i> , 2010, 17, 205-208.	1.8	13
262	Treatment of psoriasis by using Hijamah: A case report. <i>Saudi Journal of Biological Sciences</i> , 2015, 22, 117-121.	1.8	13
263	Presence of Anticardiolipin Antibodies in Patients with Dementia: A Systematic Review and Meta-Analysis. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 250.	1.7	13
264	Association of autoimmunity and cancer: An emphasis on proteolytic enzymes. <i>Seminars in Cancer Biology</i> , 2020, 64, 19-28.	4.3	13
265	Viroinformatics approach to explore the inhibitory mechanism of existing drugs repurposed to fight against COVID-19. <i>European Journal of Pharmacology</i> , 2020, 885, 173496.	1.7	13
266	Diabetic Cardiomyopathy: From Mechanism to Management in a Nutshell. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2021, 21, 268-281.	0.6	13
267	Endometrial Cancer: Genetic, Metabolic Characteristics, Therapeutic Strategies and Nanomedicine. <i>Current Medicinal Chemistry</i> , 2021, 28, 8755-8781.	1.2	13
268	Targeting COVID-19 in Parkinson's Patients: Drugs Repurposed. <i>Current Medicinal Chemistry</i> , 2021, 28, 2392-2408.	1.2	13
269	Super aggregated form of Amphotericin B: a novel way to increase its therapeutic index. <i>Current Pharmaceutical Design</i> , 2016, 22, 792-803.	0.9	13
270	Phytochemicals as Prototypes for Pharmaceutical Leads Towards Drug Development Against Diabetic Cardiomyopathy. <i>Current Pharmaceutical Design</i> , 2016, 22, 3058-3070.	0.9	13

#	ARTICLE	IF	CITATIONS
271	Potentiating Effect of Ethnomedicinal Plants Against Proliferation on Different Cancer Cell Lines. <i>Current Drug Metabolism</i> , 2018, 19, 584-595.	0.7	13
272	Role of Angiogenic Growth Factors in Psoriasis: A Review. <i>Current Drug Metabolism</i> , 2018, 19, 910-916.	0.7	13
273	Molecular Interaction and Computational Analytical Studies of Pinocebrin for its Antiangiogenic Potential Targeting VEGFR-2: A Persuader of Metastasis. <i>Medicinal Chemistry</i> , 2018, 14, 626-640.	0.7	13
274	The Mode of Inhibition of Human Erythrocyte Membrane-Bound Acetylcholinesterase by Cisplatinin Vitro. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 1995, 8, 281-289.	0.5	12
275	The inhibitory effect of cyclophosphamide on camel retina acetylcholinesterase activity. <i>Toxicology Letters</i> , 1996, 87, 69-76.	0.4	12
276	Sensitivity of bovine retinal acetylcholinesterase (E.C. 3.1.1.7) toward tacrine: Kinetic characterization. <i>Journal of Biochemical and Molecular Toxicology</i> , 1998, 12, 245-251.	1.4	12
277	Structural studies on inhibitory mechanisms of antibiotic, corticosteroid and catecholamine molecules on lactoperoxidase. <i>Life Sciences</i> , 2018, 207, 412-419.	2.0	12
278	A Computational Study of Natural Compounds from <i>Bacopa monnieri</i> in the Treatment of Alzheimer's Disease. <i>Current Pharmaceutical Design</i> , 2020, 26, 790-800.	0.9	12
279	Role of Dietary Antioxidants in Neurodegenerative Diseases: Where are We Standing?. <i>Current Pharmaceutical Design</i> , 2020, 26, 714-729.	0.9	12
280	Cross-Interplay between Osmolytes and mTOR in Alzheimer's Disease Pathogenesis. <i>Current Pharmaceutical Design</i> , 2020, 26, 4699-4711.	0.9	12
281	Application of Proteomic Tools in Modern Nanotechnological Approaches Towards Effective Management of Neurodegenerative Disorders. <i>Current Drug Metabolism</i> , 2015, 16, 376-388.	0.7	12
282	Magnetic Nanoparticles: Properties, Synthesis and Biomedical Applications. <i>Current Drug Metabolism</i> , 2015, 16, 685-704.	0.7	12
283	Viral Infection and Obesity: Current Status and Future Prospective. <i>Current Drug Metabolism</i> , 2017, 18, 798-807.	0.7	12
284	Stem Cells in Tumour Microenvironment Aid in Prolonged Survival Rate of Cancer Cells and Developed Drug Resistance: Major Challenge in Osteosarcoma Treatment. <i>Current Drug Metabolism</i> , 2020, 21, 44-52.	0.7	12
285	Roles of Natural Compounds from Medicinal Plants in Cancer Treatment: Structure and Mode of Action at Molecular Level. <i>Medicinal Chemistry</i> , 2015, 11, 618-628.	0.7	12
286	Screening and Elucidation of Selected Natural Compounds for Anti- Alzheimer's Potential Targeting BACE-1 Enzyme: A Case Computational Study. <i>Current Computer-Aided Drug Design</i> , 2017, 13, 311-318.	0.8	12
287	Molecular Interaction of the Antineoplastic Drug, Methotrexate with Human Brain Acetylcholinesterase: A Docking Study. <i>CNS and Neurological Disorders - Drug Targets</i> , 2012, 11, 142-147.	0.8	12
288	Accumulation of 5-phosphoribosyl-1-pyrophosphate in human CCRF-CEM leukaemia cells treated with antifolates. <i>International Journal of Biochemistry and Cell Biology</i> , 2004, 36, 545-551.	1.2	11

#	ARTICLE	IF	CITATIONS
289	Determination of potential role of antioxidative status and circulating biochemical markers in the pathogenesis of ethambutol induced toxic optic neuropathy among diabetic and non-diabetic patients. Saudi Journal of Biological Sciences, 2015, 22, 739-743.	1.8	11
290	Identification of common therapeutic targets for selected neurodegenerative disorders: An in silico approach. Journal of Computational Science, 2016, 17, 292-306.	1.5	11
291	Synthesis of Saccharumside-B analogue with potential of antiproliferative and pro-apoptotic activities. Scientific Reports, 2017, 7, 8309.	1.6	11
292	Pharmacological validation of the anxiolytic, muscle relaxant and sedative like activities of Capsicum annuum in animal model. Bangladesh Journal of Pharmacology, 2017, 12, 439.	0.1	11
293	The Structure and Function of $\hat{1}\pm$, $\hat{1}^2$ and $\hat{1}^3$ -Secretase as Therapeutic Target Enzymes in the Development of Alzheimer's Disease: A Review. CNS and Neurological Disorders - Drug Targets, 2020, 18, 657-667.	0.8	11
294	Drug designing against NSP15 of SARS-COV2 via high throughput computational screening and structural dynamics approach. European Journal of Pharmacology, 2021, 892, 173779.	1.7	11
295	Therapeutic Suppression of Nonsense Mutation: An Emerging Target in Multiple Diseases and Thrombotic Disorders. Current Pharmaceutical Design, 2017, 23, 1598-1609.	0.9	11
296	Comparative Study of Gene Expression Profiling Unravels Functions Associated with Pathogenesis of Dengue Infection. Current Pharmaceutical Design, 2020, 26, 5293-5299.	0.9	11
297	Potential Linkage Between Cerebrovascular Diseases and Metabolic Syndrome. Current Drug Metabolism, 2017, 18, 62-68.	0.7	11
298	A Synopsis on the Role of Human Papilloma Virus Infection in Cervical Cancer. Current Drug Metabolism, 2018, 19, 798-805.	0.7	11
299	Therapeutic Study of Phytochemicals Against Cancer and Alzheimer's Disease Management. Current Drug Metabolism, 2020, 20, 1006-1013.	0.7	11
300	Isolation and Characterization of Nuciferic Acid, a Novel Keto Fatty Acid with Hyaluronidase Inhibitory Activity from Cocos nucifera Linn. Endocarp. Current Topics in Medicinal Chemistry, 2019, 18, 2367-2378.	1.0	11
301	Synthesis of Silver Nanoparticles using Euphorbia wallichii Extract and Assessment of their Bio-functionalities. Medicinal Chemistry, 2020, 16, 495-506.	0.7	11
302	Molecular Docking Study of Catecholamines and [4-(Propan-2-yl) Phenyl] Carbamic acid with Tyrosine Hydroxylase. CNS and Neurological Disorders - Drug Targets, 2012, 11, 463-468.	0.8	11
303	Gene Expression Profiling of Early Acute Febrile Stage of Dengue Infection and Its Comparative Analysis With Streptococcus pneumoniae Infection. Frontiers in Cellular and Infection Microbiology, 2021, 11, 707905.	1.8	11
304	Smartphone Addiction among Students and its Harmful Effects on Mental Health, Oxidative Stress, and Neurodegeneration towards Future Modulation of Anti-Addiction Therapies: A Comprehensive Survey based on SLR, Research Questions, and Network Visualization Techniques. CNS and Neurological Disorders - Drug Targets, 2023, 22, 1070-1089.	0.8	11
305	Neurine, an acetylcholine autolysis product, elevates secreted amyloid- $\hat{1}^2$ protein precursor and amyloid- $\hat{1}^2$ peptide levels, and lowers neuronal cell viability in culture: A role in Alzheimer's disease?. Journal of Alzheimer's Disease, 2006, 10, 9-16.	1.2	10
306	Anti-Inflammatory Properties of Acetylcholinesterase Inhibitors Administred in Alzheimers Disease. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2009, 8, 85-100.	1.1	10

#	ARTICLE	IF	CITATIONS
307	Current Challenges to Overcome in the Management of Type 2 Diabetes Mellitus and Associated Neurological Disorders. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 1440-1457.	0.8	10
308	Nanoinformatics and biomolecular nanomodeling: a novel move en route for effective cancer treatment. <i>Environmental Science and Pollution Research</i> , 2020, 27, 19127-19141.	2.7	10
309	A Direct Method for RT-PCR Detection of SARS-CoV-2 in Clinical Samples. <i>Healthcare (Switzerland)</i> , 2021, 9, 37.	1.0	10
310	Interaction of Ectodomain of Respiratory Syncytial Virus G Protein with TLR2/ TLR6 Heterodimer: An In vitro and In silico Approach to Decipher the Role of RSV G Protein in Pro-inflammatory Response against the Virus. <i>Current Pharmaceutical Design</i> , 2021, 27, 4464-4476.	0.9	10
311	The Regulatory Roles of Long Non-Coding RNA in the Chemoresistance Process of Ovarian cancer. <i>Current Pharmaceutical Design</i> , 2019, 25, 856-861.	0.9	10
312	Inhibitory Mechanism of An Anticancer Drug, Bexarotene Against Amyloid β^2 Peptide Aggregation: Repurposing Via Neuroinformatics Approach. <i>Current Pharmaceutical Design</i> , 2019, 25, 2989-2995.	0.9	10
313	Preclinical Hepatoprotective Effect of Herbalism Against Ethanol Induced Hepatotoxicity: A Review. <i>Current Drug Metabolism</i> , 2018, 19, 1002-1011.	0.7	10
314	An Increasing Role of Polyphenols as Novel Therapeutics for Alzheimer's™s: A Review. <i>Medicinal Chemistry</i> , 2020, 16, 1007-1021.	0.7	10
315	Cancer Nanotechnology-An Excursion on Drug Delivery Systems. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 18, 2078-2092.	0.9	10
316	An Overview on Potential Neuroprotective Compounds for Management of Alzheimer's™s Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2013, 11, 1006-1011.	0.8	10
317	Ignored Avenues in Alpha-Synuclein Associated Proteopathy. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 1246-1257.	0.8	10
318	Sub-Chronic Exposure of Non-Observable Adverse Effect Dose of Terbufos Sulfone: Neuroinflammation in Diabetic and Non-Diabetic Rats. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 1397-1405.	0.8	10
319	Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their Role in the Treatment of Cancer: A Review. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 3370-3381.	0.9	10
320	Multi-staged gene expression profiling reveals potential genes and the critical pathways in kidney cancer. <i>Scientific Reports</i> , 2022, 12, 7240.	1.6	10
321	Application of Artificial Intelligence in Drug Discovery. <i>Current Pharmaceutical Design</i> , 2022, 28, 2690-2703.	0.9	10
322	An enoinformatics study targeting polo-like kinases-1 enzyme: Comparative assessment of anticancer potential of compounds isolated from leaves of <i>Ageratum houstonianum</i> . <i>Pharmacognosy Magazine</i> , 2014, 10, 14.	0.3	9
323	Studies on the role of goat heart galectin-1 as a tool for detecting post-malignant changes in glycosylation pattern. <i>Saudi Journal of Biological Sciences</i> , 2015, 22, 85-89.	1.8	9
324	Pharmacokinetics and safety of oseltamivir in patients with end-stage renal disease treated with automated peritoneal dialysis. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 624-635.	1.1	9

#	ARTICLE	IF	CITATIONS
325	Role of viruses, prions and miRNA in neurodegenerative disorders and dementia. <i>VirusDisease</i> , 2018, 29, 419-433.	1.0	9
326	From Molecular Mechanism to the Etiology of Sjogren Syndrome. <i>Current Pharmaceutical Design</i> , 2019, 24, 4177-4185.	0.9	9
327	Structural insights into the camel milk lactoperoxidase: Homology modeling and molecular dynamics simulation studies. <i>Journal of Molecular Graphics and Modelling</i> , 2019, 86, 43-51.	1.3	9
328	Dominance of the ON1 Genotype of RSV-A and BA9 Genotype of RSV-B in Respiratory Cases from Jeddah, Saudi Arabia. <i>Genes</i> , 2020, 11, 1323.	1.0	9
329	Impact of Traditional Plants and their Secondary Metabolites in the Discovery of COVID-19 Treatment. <i>Current Pharmaceutical Design</i> , 2021, 27, 1123-1143.	0.9	9
330	Current Overviews on COVID-19 Management Strategies. <i>Current Pharmaceutical Biotechnology</i> , 2021, 22, .	0.9	9
331	DARPin Bioengineering and its Theranostic Approaches: Emerging Trends in Protein Engineering. <i>Current Pharmaceutical Design</i> , 2017, 23, 1610-1615.	0.9	9
332	Ajmalicine and its Analogues Against AChE and BuChE for the Management of Alzheimer's Disease: An In-silico Study. <i>Current Pharmaceutical Design</i> , 2020, 26, 4808-4814.	0.9	9
333	The Emergence of Human Pathogenic Coronaviruses: Lectins as Antivirals for SARS-CoV-2. <i>Current Pharmaceutical Design</i> , 2020, 26, 5286-5292.	0.9	9
334	Therapeutic Interventions for the Suppression of Alzheimer's Disease: Quest for a Remedy. <i>Current Drug Metabolism</i> , 2015, 16, 346-353.	0.7	9
335	Challenges Related to Glycemic Control in Type 2 Diabetes Mellitus Patients. <i>Current Drug Metabolism</i> , 2017, 18, 157-162.	0.7	9
336	Molecular Interaction Study of N1-p-fluorobenzyl-cymserine with TNF- α , p38 Kinase and JNK Kinase. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2013, 12, 129-135.	1.1	9
337	Array-Comparative Genomic Hybridization Analysis of a Cohort of Saudi Patients with Epilepsy. <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 14, 468-475.	0.8	9
338	Prospects for Discovering the Secondary Metabolites of Cordyceps Sensu Lato by the Integrated Strategy. <i>Medicinal Chemistry</i> , 2020, 17, 97-120.	0.7	9
339	E6 and E7 Oncoproteins: Potential Targets of Cervical Cancer. <i>Current Medicinal Chemistry</i> , 2021, 28, 8163-8181.	1.2	9
340	COVID-19 diagnostic methods in developing countries. <i>Environmental Science and Pollution Research</i> , 2022, 29, 51384-51397.	2.7	9
341	Kinetics for Camel (<i>Camelus dromedarius</i>) Retina Acetylcholinesterase Inhibition by Methotrexate In Vitro. <i>The Japanese Journal of Pharmacology</i> , 1996, 72, 49-55.	1.2	8
342	Multiple Approaches to Analyse the Data for Rat Brain Acetylcholinesterase Inhibition by Cyclophosphamide. <i>Neurochemical Research</i> , 2010, 35, 1501-1509.	1.6	8

#	ARTICLE	IF	CITATIONS
343	Interaction of Glucagon G-Protein Coupled Receptor with Known Natural Antidiabetic Compounds: Multiscoring<i>In Silico</i>Approach. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-6.	0.5	8
344	Development of interspecific Solanum lycopersicum and screening for Tosopvirus resistance. Saudi Journal of Biological Sciences, 2015, 22, 730-738.	1.8	8
345	Plant-derived mPGES-1 inhibitors or suppressors: A new emerging trend in the search for small molecules to combat inflammation. European Journal of Medicinal Chemistry, 2018, 153, 2-28.	2.6	8
346	A Critical Appraisal of Different Food Safety and Quality Management Tools to Accomplish Food Safety. , 2018, , 1-12.		8
347	Molecular mechanisms of interplay between autophagy and metabolism in cancer. Life Sciences, 2020, 259, 118184.	2.0	8
348	Molecular docking of alpha-enolase to elucidate the promising candidates against Streptococcus pneumoniae infection. DARU, Journal of Pharmaceutical Sciences, 2021, 29, 73-84.	0.9	8
349	Epigenetics of Triple-Negative Breast Cancer via Natural Compounds. Current Medicinal Chemistry, 2022, 29, 1436-1458.	1.2	8
350	Nanobiotechnological Approaches Against Multidrug Resistant Bacterial Pathogens: An Update. Current Drug Metabolism, 2015, 16, 362-370.	0.7	8
351	An Overview of Current Screening and Management Approaches for Prostate Cancer. Current Drug Metabolism, 2015, 16, 713-718.	0.7	8
352	Exploration of Various Proteins for the Treatment of Alzheimer's Disease. Current Drug Metabolism, 2017, 18, 808-813.	0.7	8
353	Elucidation of Antiangiogenic Potential of Vitexin Obtained from Cucumis sativus Targeting Hsp90 Protein: A Novel Multipathway Targeted Approach to Restrain Angiogenic Phenomena. Medicinal Chemistry, 2017, 13, 282-291.	0.7	8
354	Protein Interactions Between the C-Terminus of Aβ-Peptide and Phospholipase A₂ - A Structure Biology Based Approach to Identify Novel Alzheimerâ€™s Therapeutics. CNS and Neurological Disorders - Drug Targets, 2014, 13, 1224-1231.	0.8	8
355	Updates on Therapeutics in Clinical Trials for Spinal Cord Injuries: Key Translational Applications of Human Embryonic Stem Cells-Derived Neural Progenitors. CNS and Neurological Disorders - Drug Targets, 2016, 15, 1266-1278.	0.8	8
356	Evaluation of Hemoglobin Concentration in Pregnancy and Correlation with Different Altitude: A Study from Balochistan Plateau of Pakistan. The Open Biochemistry Journal, 2015, 9, 7-14.	0.3	8
357	Edible Nuts for Memory. Current Pharmaceutical Design, 2020, 26, 4712-4720.	0.9	8
358	Therapeutic and pharmacological potential of Tanshinones against lung cancer: A systematic review. Phytomedicine Plus, 2022, 2, 100202.	0.9	8
359	Elucidations of Molecular Mechanism and Mechanistic Effects of Environmental Toxicants in Neurological Disorders. CNS and Neurological Disorders - Drug Targets, 2023, 22, 84-97.	0.8	8
360	Thermodynamic Investigation of Camel Retina Acetylcholinesterase Inhibition by Cyclophosphamide. Journal of Enzyme Inhibition and Medicinal Chemistry, 1997, 11, 275-283.	0.5	7

#	ARTICLE	IF	CITATIONS
361	Studies on the role of goat heart galectin-1 as an erythrocyte membrane perturbing agent. Saudi Journal of Biological Sciences, 2015, 22, 112-116.	1.8	7
362	Study of Nutraceuticals and Phytochemicals for the Management of Alzheimer's Disease: A Review. Current Neuropharmacology, 2021, 19, 1884-1895.	1.4	7
363	The Computational Intervention of Macrolide Antibiotics in the Treatment of COVID-19. Current Pharmaceutical Design, 2021, 27, 1202-1210.	0.9	7
364	Prediction of Structure of Human WNT-CRD (FZD) Complex for Computational Drug Repurposing. PLoS ONE, 2013, 8, e54630.	1.1	7
365	Role of ATP-Binding Cassette Transporter Proteins in CNS Tumors: Resistance- Based Perspectives and Clinical Updates. Current Pharmaceutical Design, 2020, 26, 4747-4763.	0.9	7
366	Marine Drugs: A Hidden Wealth and a New Epoch for Cancer Management. Current Drug Metabolism, 2018, 19, 523-543.	0.7	7
367	In Silico Structure Modeling and Molecular Docking Analysis of Phosphoribosyl Pyrophosphate Amidotransferase (PPAT) with Antifolate Inhibitors. Current Cancer Drug Targets, 2019, 19, 408-416.	0.8	7
368	In silico Screening for Identification of Novel Anti-malarial Inhibitors by Molecular Docking, Pharmacophore Modeling and Virtual Screening. Medicinal Chemistry, 2015, 11, 687-700.	0.7	7
369	Comparative Study of Non-High Density Lipoproteins Cholesterol Level and Lipid Profile in Pre-Diabetic and Diabetic Patients. CNS and Neurological Disorders - Drug Targets, 2014, 13, 402-407.	0.8	7
370	Epigenomic Approach in Understanding Alzheimer's Disease and Type 2 Diabetes Mellitus. CNS and Neurological Disorders - Drug Targets, 2014, 13, 283-289.	0.8	7
371	Inhibition of Neurogenesis by Zika Virus Infection. CNS and Neurological Disorders - Drug Targets, 2018, 17, 78-86.	0.8	7
372	Exploring the Recent Trends in Management of Dementia and Frailty: Focus on Diagnosis and Treatment. Current Medicinal Chemistry, 2022, 29, 5289-5314.	1.2	7
373	The Preparation and Kinetic Analysis of Multiple Forms of Human Erythrocyte Acetylcholinesterase. Preparative Biochemistry and Biotechnology, 1996, 26, 105-119.	1.0	6
374	In silico analysis of glycinamide ribonucleotide transformylase inhibition by PY873, PY899 and DIA. Saudi Journal of Biological Sciences, 2017, 24, 1155-1161.	1.8	6
375	From Oxidative Stress to Ageing via Lifestyle, Nutraceuticals, Polypharmacy, and Neuropsychological Factors. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-2.	1.9	6
376	Antidepressant Potential of Peptides: New Insights as Future Therapeutic. CNS and Neurological Disorders - Drug Targets, 2018, 17, 9-13.	0.8	6
377	Influence of Hormones on Sjögren's Syndrome. Current Pharmaceutical Design, 2019, 24, 4167-4176.	0.9	6
378	Potential of Plant Alkaloids as Antipyretic Drugs of Future. Current Drug Metabolism, 2017, 18, 138-144.	0.7	6

#	ARTICLE	IF	CITATIONS
379	Methods of Screening-Purification and Antimicrobial Potentialities of Bacteriocin in Health Care. <i>Current Drug Metabolism</i> , 2017, 18, 814-830.	0.7	6
380	Versatile and Valuable Utilization of Amidohydrolase L-glutaminase in Pharma and Food industries: A Review. <i>Current Drug Metabolism</i> , 2020, 21, 11-24.	0.7	6
381	Bacteriophage - A Common Divergent Therapeutic Approach for Alzheimer's Disease and Type II Diabetes Mellitus. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 491-500.	0.8	6
382	Effect of Electromagnetic Radiations on Neurodegenerative Diseases- Technological Revolution as a Curse in Disguise. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 1406-1412.	0.8	6
383	Global Expression Studies of Schizophrenic Brain: A Meta-Analysis Study Linking Neurological Immune System with Psychological Disorders. <i>CNS and Neurological Disorders - Drug Targets</i> , 2016, 15, 477-488.	0.8	6
384	Bibliometric Analysis of Current Drug Metabolism: The Twentieth Anniversary from 2000-2019. <i>Current Drug Metabolism</i> , 2020, 21, 685-703.	0.7	6
385	Therapeutic role of flavonoids in lung inflammatory disorders. <i>Phytomedicine Plus</i> , 2022, 2, 100221.	0.9	6
386	Recent Advances of Nanotechnology in the Diagnosis and Therapy of Triple- Negative Breast Cancer (TNBC). <i>Current Pharmaceutical Biotechnology</i> , 2022, 23, 1581-1595.	0.9	6
387	In vitro inhibition of human erythrocyte acetylcholinesterase (EC3.1.1.7) by an antineoplastic drug methotrexate. <i>Molecular and Cellular Biochemistry</i> , 1996, 159, 47-53.	1.4	5
388	Evaluation of the Nature of Camel Retinal Acetylcholinesterase: Inhibition by Hexamethonium. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 1997, 12, 303-311.	0.5	5
389	Human erythrocyte acetylcholinesterase inhibition by cis-diamminediaquaplatinum (II): a novel kinetic approach. <i>Cancer Letters</i> , 1999, 138, 115-119.	3.2	5
390	Evaluation of antioxidant and antimicrobial activities of the phenolic composition of Algerian <i>Arbutus unedo</i> L. roots. <i>Pharmacognosy Journal</i> , 2013, 5, 275-280.	0.3	5
391	Specific Cholinesterase Inhibitors: A Potential Tool to Assist in Management of Alzheimer Disease. , 2014, , 366-386.		5
392	Pharmacophore-Based Virtual Screening for Identification of Novel Neuraminidase Inhibitors and Verification of Inhibitory Activity by Molecular Docking. <i>Medicinal Chemistry</i> , 2016, 12, 63-73.	0.7	5
393	Deciphering the SSR incidences across viral members of Coronaviridae family. <i>Chemico-Biological Interactions</i> , 2020, 331, 109226.	1.7	5
394	Particulate β -glucan activates early and delayed phagosomal maturation and autophagy within macrophage in a NOX-2 dependent manner. <i>Life Sciences</i> , 2021, 266, 118851.	2.0	5
395	QSCR Analysis of Cytotoxicity of 6-Fluoro-3-(4H-1,2,4-triazol-3-yl)quinolin-4(1H)-ones on Chinese Hamster Ovary Cell Line: Design of REPUBLIC1986. <i>Current Medicinal Chemistry</i> , 2021, 28, .	1.2	5
396	Antimicrobial and Antifungal Properties of Leaves to Root Extracts and Saponin Fractions of <i>Chlorophytum borivilianum</i> . <i>Current Bioactive Compounds</i> , 2021, 17, .	0.2	5

#	ARTICLE	IF	CITATIONS
397	Chemokines: A Potential Therapeutic Target to Suppress Autoimmune Arthritis. <i>Current Pharmaceutical Design</i> , 2019, 25, 2937-2946.	0.9	5
398	Frontier View on Nanotechnological Strategies for Neuro-therapy. <i>Current Drug Metabolism</i> , 2018, 19, 596-604.	0.7	5
399	Thrombotic Management of Antiphospholipid Syndrome: Towards Novel Targeted Therapies. <i>Current Vascular Pharmacology</i> , 2017, 15, 313-326.	0.8	5
400	Common Therapeutic Modalities Against Diabetes and Associated Cardiovascular Disease. <i>Current Vascular Pharmacology</i> , 2017, 15, 365-373.	0.8	5
401	Cardiac Biomarkers in Stroke, Alzheimer's Disease, and Other Dementia. Are They of Use? A Brief Overview of Data from Recent Investigations. <i>CNS and Neurological Disorders - Drug Targets</i> , 2020, 19, 687-693.	0.8	5
402	Natural Products Homoharringtonine and Emetine Alkaloids as SARS-CoV-2 Treatment Options. <i>Current Pharmaceutical Design</i> , 2021, 27, 3444-3453.	0.9	5
403	Can manipulation of gut microbiota really be transformed into an intervention strategy for cardiovascular disease management?. <i>Folia Microbiologica</i> , 2021, 66, 897-916.	1.1	5
404	The Language Development Via FOXP2 in Autism Spectrum Disorder: A Review. <i>Current Pharmaceutical Design</i> , 2020, 26, 4789-4795.	0.9	5
405	In Silico and Ex Vivo Analyses of the Inhibitory Action of the Alzheimer Drug Posiphen and Primary Metabolites with Human Acetyl- and Butyrylcholinesterase Enzymes. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 70-79.	2.5	5
406	Nanotechnology: A Promising Targeted Drug Delivery System for Brain Tumours and Alzheimer's Disease. <i>Current Medicinal Chemistry</i> , 2023, 30, 255-270.	1.2	5
407	Role of G-Proteins and GPCR-Mediated Signalling in Neuropathophysiology. <i>CNS and Neurological Disorders - Drug Targets</i> , 2023, 22, 2-5.	0.8	5
408	Kinetics of the inhibition of acetylcholinesterase in camel retina by cisplatin. <i>Cancer Letters</i> , 1998, 128, 79-86.	3.2	4
409	In silico analysis of the amido phosphoribosyltransferase inhibition by PY873, PY899 and a derivative of isophthalic acid. <i>Investigational New Drugs</i> , 2013, 31, 1355-1363.	1.2	4
410	Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside) <i>Tj ETQq0 0 0 rgBT /Overlock 10</i> 515-517.	0.9	4
411	Editorial: Structured Nanosystems for Dermal Delivery of Therapeutics: Options, Opportunities and Clinical Implications. <i>Current Drug Metabolism</i> , 2017, 18, 402-403.	0.7	4
412	Current Updates on the Regulation of Beta-Secretase Movement as a Potential Restorative Focus for Management of Alzheimer's Disease. <i>Protein and Peptide Letters</i> , 2019, 26, 579-587.	0.4	4
413	Effect of Diterpenes on Hepatic System. <i>Current Pharmaceutical Design</i> , 2019, 24, 4093-4100.	0.9	4
414	Synthesis, anticancer evaluation and molecular docking studies of methotrexate's novel Schiff base derivatives against malignant glioma cell lines. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 2865-2877.	2.0	4

#	ARTICLE	IF	CITATIONS
415	Promiscuous Biological Features of Newly Emerged SARS-CoV-2 Facilitate its Unrestrained Outbreak: An Update. <i>Coronaviruses</i> , 2021, 2, .	0.2	4
416	Natural products: Potential targets of TME related long non-coding RNAs in lung cancer. <i>Phytomedicine</i> , 2021, 93, 153782.	2.3	4
417	Spectrum from Obesity to Neurodegenerative Disorder. <i>American Journal of Neuroprotection and Neuroregeneration</i> , 2012, 4, 31-39.	0.1	4
418	Antiplatelet Potential of Plant-Derived Glycosides as Possible Lead Compounds. <i>Current Drug Metabolism</i> , 2018, 19, 856-862.	0.7	4
419	Relationship between CNS and Immunology: Correlation with Psychology. <i>Current Drug Metabolism</i> , 2018, 19, 847-855.	0.7	4
420	Recent Findings on Nanotechnology-based Therapeutic Strategies Against Hepatocellular Carcinoma. <i>Current Drug Metabolism</i> , 2019, 20, 283-291.	0.7	4
421	Human Platelet Acetylcholinesterase Inhibition by Cyclophosphamide: A Combined Experimental and Computational Approach. <i>CNS and Neurological Disorders - Drug Targets</i> , 2011, 10, 928-935.	0.8	4
422	Exosomes: Critical mediators of tumour microenvironment reprogramming. <i>Current Medicinal Chemistry</i> , 2020, 28, .	1.2	4
423	<i>Antrodia cinnamomea</i> Inhibits Growth and Migration of Lung Cancer Cells through Regulating p53-Bcl2 and MMPs Pathways. <i>The American Journal of Chinese Medicine</i> , 2020, 48, 1941-1953.	1.5	4
424	Can We Use mTOR Inhibitors for COVID-19 Therapy?. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2022, 25, 1805-1808.	0.6	4
425	A Critical Analysis of Quercetin as the Attractive Target for the Treatment of Parkinson's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2022, 21, 795-817.	0.8	4
426	Nanoparticles Mediated Target-specific Drug Delivery in Prostate Cancer: An In-depth Review. <i>Current Medicinal Chemistry</i> , 2022, 29, 4170-4184.	1.2	4
427	Efficacy of <i>Acacia nilotica</i> Linn. Podâ€™s Sitz Bath plus Vaginal Pessary in Syndromic Management of Abnormal Vaginal Discharge: A Randomized Controlled Trial. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-11.	0.5	4
428	Theranostic Potentials of Gold Nanomaterials in Hematological Malignancies. <i>Cancers</i> , 2022, 14, 3047.	1.7	4
429	On the inhibition of camel retina acetylcholinesterase activity by cycloheximide in vitro. <i>Cell Biology and Toxicology</i> , 1998, 14, 167-174.	2.4	3
430	Medicinal Plants in Management of Type 2 Diabetes and Neurodegenerative Disorders. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-2.	0.5	3
431	Lateral meningocele with asymmetric canal stenosis: A case study. <i>Saudi Journal of Biological Sciences</i> , 2015, 22, 102-105.	1.8	3
432	Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside) <i>Tj ETQqO O O rgBT /Overlock 10</i> 2016, 22, 2923-2925.	0.9	3

#	ARTICLE	IF	CITATIONS
433	Editorial: Frontier Views in Designing Therapeutic Candidates for Management of Diverse Diseases. <i>Current Pharmaceutical Design</i> , 2017, 23, 1571-1574.	0.9	3
434	Complementary and Integrative Medicine: Personalized Health Care for Cancer and Chronic Inflammatory Diseases. <i>Current Pharmaceutical Design</i> , 2019, 24, 4091-4092.	0.9	3
435	Assessment of Circulating Biochemical Markers in Mice Receiving Cinnamon and Glycyrrhizin Under Carbon Tetrachloride Induced Hepatic Injury. <i>Proceedings of the National Academy of Sciences India Section B - Biological Sciences</i> , 2019, 89, 105-111.	0.4	3
436	Autoimmune disease and cancer comorbidity: Current understandings of immune-mediated pathogenesis and treatment. <i>Seminars in Cancer Biology</i> , 2020, 64, iii-iv.	4.3	3
437	Cellular and molecular mechanisms of Dementia: Decoding the causal link of Diabetes Mellitus in Alzheimer's disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2021, 20, 602-612.	0.8	3
438	Clinical Characteristics of the First 100 Patients of COVID-19 in Tobruk, Libya: A Brief Report From Low-Resource Settings. <i>Disaster Medicine and Public Health Preparedness</i> , 2021, , 1-4.	0.7	3
439	Synopsis of Pharmotechnological Approaches in Diagnostic and Management Strategies for Fighting Against COVID-19. <i>Current Pharmaceutical Design</i> , 2021, 27, 4086-4099.	0.9	3
440	ROS-Responsive Nanomedicine: Towards Targeting the Breast Tumor Microenvironment. <i>Current Medicinal Chemistry</i> , 2021, 28, 5674-5698.	1.2	3
441	Recent Developments in Nanomedicines for Management of Various Health Issues Via Metabolism and Physico-Chemical Properties. <i>Current Drug Metabolism</i> , 2015, 16, 389-396.	0.7	3
442	Glycosides as Possible Lead Antimalarial in New Drug Discovery: Future Perspectives. <i>Current Drug Metabolism</i> , 2017, 18, 163-171.	0.7	3
443	In silico analysis for predicting fatty acids of black cummin oil as inhibitors of P-glycoprotein. <i>Pharmacognosy Magazine</i> , 2015, 11, 606.	0.3	3
444	Exploring N ¹ -p-Fluorobenzyl-Cymserine as an Inhibitor of 5-Lipoxygenase as a Candidate for Type 2 Diabetes and Neurodegenerative Disorder Treatment. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 197-202.	0.8	3
445	Lactoperoxidase, an Antimicrobial Milk Protein, as a Potential Activator of Carcinogenic Heterocyclic Amines in Breast Cancer. <i>Anticancer Research</i> , 2017, 37, 6415-6420.	0.5	3
446	Synergistic Molecular Effect of BDNF, ApoE and MTHFR in inducing Depression in Alzheimer's Disease. <i>Research Journal of Pharmacy and Technology</i> , 2018, 11, 4317.	0.2	3
447	In-silico Studies of Isolated Phytoalkaloid Against Lipoxygenase: Study Based on Possible Correlation. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2018, 21, 215-221.	0.6	3
448	Characterization of human erythrocyte membrane-bound acetylcholinesterase inhibition by cisplatin at reversible phase. <i>Anticancer Research</i> , 1996, 16, 3725-30.	0.5	3
449	Kinetics of human erythrocyte acetylcholinesterase inhibition by cis-diamminediaquaplatinum (II). <i>Anticancer Research</i> , 1997, 17, 4487-91.	0.5	3
450	Mechanism of Mesenchymal Stem Cells as a Multitarget Disease- Modifying Therapy for Parkinson's Disease. <i>Current Neuropharmacology</i> , 2023, 21, 988-1000.	1.4	3

#	ARTICLE	IF	CITATIONS
451	Antifungal Activity of Plant Secondary Metabolites on <i>Candida albicans</i> : An Updated Review. <i>Current Molecular Pharmacology</i> , 2023, 16, 15-42.	0.7	3
452	Investigation of the effect of tetrahydroaminoacridine on turnover kinetics of camel (<i>Camelus</i>) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 307 T	1.5	2
453	Investigation of the effect of anti-neoplastic drugs, cyclophosphamide, cisplatin and methotrexate on the turnover kinetics of human erythrocyte acetylcholinesterase. <i>IUBMB Life</i> , 1996, 39, 293-302.	1.5	2
454	Kinetics of the Inhibition of Acetylcholinesterase from Desert Cobra (<i>Walterzennesza Aegyptza</i>) Venom by Local Anesthetics: Procaine and Tetracaine. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 1996, 11, 123-134.	0.5	2
455	Dual temperature model for the estimation of energetics parameters for acetylcholinesterase inhibition by cyclophosphamide. <i>IUBMB Life</i> , 1997, 43, 571-581.	1.5	2
456	Investigation of the effect of lannate on kinetic parameters of acetylcholinesterase: Slightly concave mixed-type of inhibition system. <i>IUBMB Life</i> , 1997, 43, 1183-1193.	1.5	2
457	Dual Substrate Model for Novel Approach Towards a Kinetic Study of Acetylcholinesterase Inhibition by Diazinon. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2000, 15, 201-213.	0.5	2
458	Editorial [Hot Topic: Status of Tyrosine Hydroxylase in the Healthy and Parkinson's Brain (Guest) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 4	0.8	2
459	Editorial (Thematic Issue: Global Trends in Nanotechnological Approaches for Various Health Issues " Tj ETQq1 1,0,784314 rgBT /O	0.7	2
460	Biological aspect of various global health issues. <i>Saudi Journal of Biological Sciences</i> , 2015, 22, 1-2.	1.8	2
461	Immune-mediated Pathogenesis and Therapies for Inflammatory Autoimmune Diseases. <i>Current Pharmaceutical Design</i> , 2019, 25, 2907-2908.	0.9	2
462	Interaction of human dynein light chain 1 (DYNLL1) with enterochelin esterase (<i>Salmonella</i>) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 307 T infection. <i>Saudi Journal of Biological Sciences</i> , 2020, 27, 1396-1402.	1.8	2
463	Emerging therapeutic approaches to COVID-19. <i>Current Pharmaceutical Design</i> , 2021, 27, 3370-3388.	0.9	2
464	Sleep Disorders Research From 1945 to 2020: A Bibliometric Analysis. <i>CNS and Neurological Disorders - Drug Targets</i> , 2021, 20, 574-593.	0.8	2
465	Functional Neuroproteomics: An imperative approach for unravelling protein implicated complexities of brain.. <i>CNS and Neurological Disorders - Drug Targets</i> , 2021, 20, 613-624.	0.8	2
466	Health Science Community Will Miss This Bright and Uniting Star: In Memory of Professor Gjumrakch Aliev, M.D, Ph.D.. <i>Cancers</i> , 2021, 13, 1965.	1.7	2
467	Polyphenols as Modulators of Oxidative Stress in Cancer Disease. , 2021, , 143-188.		2
468	Dissociation Between the Potent β -Amyloid Protein Pathway Inhibition and Cholinergic Actions of the Alzheimer Drug Candidates Phenserine and Cymserine. , 2008, , 445-462.		2

#	ARTICLE	IF	CITATIONS
469	In silico Analysis of AMP-activated Protein Kinase and Ligand-based Virtual Screening for Identification of Novel AMPK Activators. <i>Current Computer-Aided Drug Design</i> , 2017, 13, 222-233.	0.8	2
470	Gene Expression Analysis Approach to Establish Possible Links Between Parkinson's Disease, Cancer and Cardiovascular Diseases. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 1334-1345.	0.8	2
471	The Role of Endoproteolytic Processing in Neurodegeneration. <i>CNS and Neurological Disorders - Drug Targets</i> , 2016, 15, 1222-1230.	0.8	2
472	Coronavirus Disease-2019 (COVID-19) in 2020: A Perspective Study of a Global Pandemic. <i>Current Pharmaceutical Design</i> , 2021, 27, 3435-3443.	0.9	2
473	Computational Study of Human Tyrosine Hydroxylase Mutants to Uphold [4-(Propan-2-yl)Phenyl]Carbamic Acid as a Potential Inhibitor. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 1169-1174.	0.8	2
474	Scope and Applications of Nanomedicines for the Management of Multiple Sclerosis. <i>Current Drug Metabolism</i> , 2015, 16, 602-608.	0.7	2
475	Decoding the Inter-Relationship between Sleep Disorders and Alzheimer's Disease Pathogenesis. <i>CNS and Neurological Disorders - Drug Targets</i> , 2021, 20, 723-735.	0.8	2
476	NMR: From Molecular Mechanism to its Application in Medical Care. <i>Medicinal Chemistry</i> , 2020, 16, 1089-1098.	0.7	2
477	The Current Evidence for the Therapeutic Role of Curcumin in Alzheimer's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2023, 22, 318-320.	0.8	2
478	miRNAs in SARS-CoV-2 Infection: An Update. <i>Current Drug Metabolism</i> , 2022, 23, .	0.7	2
479	A Review of the Rational and Current Evidence on Colchicine for COVID-19. <i>Current Pharmaceutical Design</i> , 2022, 28, 3194-3201.	0.9	2
480	Novel approaches for the application of Herbs for Skin Care.. <i>Current Pharmaceutical Biotechnology</i> , 2022, 23, .	0.9	2
481	Nanoinformatics and Personalized Medicine: An Advanced Cumulative Approach for Cancer Management. <i>Current Medicinal Chemistry</i> , 2023, 30, 271-285.	1.2	2
482	Kinetic constants for the inhibition of camel retinal acetylcholinesterase by the carbamate insecticide lannate. , 1999, 13, 41-46.		1
483	Editorial (Thematic Issue: Current Update on Association Between Alzheimer's Disease and Type 2) <i>Tj ETQq1 1 0.784314 rgBT /Over</i>	0.8	1
484	Editorial (Thematic Issue: Linkage of Neurodegenerative Disorders with Other Health Issues " Volume) <i>Tj ETQq0 0.0 rgBT /Qverlock 10</i>	0.8	1
485	Editorial (Thematic Issue: Current Updates on Association Between Alzheimer's Disease and Type 2) <i>Tj ETQq1 1 0.784314 rgBT /Over</i>	0.8	1
486	Editorial (Thematic Issue: Global Trends for Nanotechnological Approaches in Various Health Issues -) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf</i>	0.7	1

#	ARTICLE	IF	CITATIONS
487	Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside) Tj ETQq1 1 0.784314 rgBT /Omel 2016, 22, 4337-4340.	0.9	1
488	Targeting Arachidonic Acid Pathway-Associated NF- κ B in Pancreatic Cancer. , 2017, , 403-411.		1
489	Editorial (Thematic Issue : Frontier View on Drug Discoveries for Different Diseases - Part I). Current Drug Metabolism, 2017, 18, 3-4.	0.7	1
490	Editorial: Alzheimer's Disease: From Molecular Mechanisms to Psychobiological Perspectives. Current Alzheimer Research, 2017, 14, 1138-1139.	0.7	1
491	MHC binding peptides for designing of vaccines against Japanese encephalitis virus: A computational approach. Saudi Journal of Biological Sciences, 2018, 25, 1546-1551.	1.8	1
492	Editorial: Current Vision of Systemic Autoimmune Diseases - From Diagnosis to Management Systemic. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2018, 18, 96-97.	0.6	1
493	Concept of Drug Metabolism in Drug Discovery Pipeline. Current Drug Metabolism, 2019, 20, 697-700.	0.7	1
494	Current Genetic and Epigenetic Insights into Type 2 Diabetes Mellitus. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2019, 19, 717-718.	0.6	1
495	Screening and Identification of PLK1-Polo Box Binding Peptides by High-Throughput Sequencing of Phage-Selected Libraries. Protein and Peptide Letters, 2019, 26, 620-633.	0.4	1
496	Nonpharmacologic Interventions in Prevention and Treatment of Hypertension. International Journal of Hypertension, 2019, 2019, 1-2.	0.5	1
497	Editorial: Neuroscientific Research for Management of Dementia. Frontiers in Aging Neuroscience, 2019, 11, 31.	1.7	1
498	Trends in Photocatalysis Research from the Year 2000 to 2020. Current Organocatalysis, 2021, 8, 362-379.	0.3	1
499	Viral Diseases and Natural Products: Prospects in COVID-19 Treatment (Part II). Current Pharmaceutical Design, 2021, 27, 1121-1122.	0.9	1
500	Elachi Lemon (Citrus limon) Peel and Pulp: Antioxidant, Antimicrobial, Anticoagulant Activities, Bioactive Compounds, Minerals, and Heavy Metals. Current Bioactive Compounds, 2021, 17, .	0.2	1
501	Nanotechnology-Based Advancements in Postharvest Management of Horticultural Crops. Phytion, 2022, 91, 471-487.	0.4	1
502	Integrating Qualitative and Quantitative Tools for the Detection and Identification of Lectins in Major Human Diseases. Protein and Peptide Letters, 2015, 22, 954-962.	0.4	1
503	Structure Activity Relationship of Venom Toxins Targeting Potassium Channels. Current Drug Metabolism, 2018, 19, 714-720.	0.7	1
504	In Silico Analysis of Binding Interaction of Mamba Toxins with M4 and M2 Muscarinic Acetylcholine Receptors for Therapeutic Use in Alzheimer's Disease. CNS and Neurological Disorders - Drug Targets, 2015, 14, 1031-1040.	0.8	1

#	ARTICLE	IF	CITATIONS
505	Genomic Linkage Between Alzheimer's Disease and Type 2 Diabetes. CNS and Neurological Disorders - Drug Targets, 2014, 13, 203-212.	0.8	1
506	Nanoparticle-Based Therapy in Genomics. Current Drug Metabolism, 2015, 16, 354-361.	0.7	1
507	Computational Protein-Protein Docking Reveals the Therapeutic Potential of Kunitz-type Venom against hKv1.2 Binding Sites. CNS and Neurological Disorders - Drug Targets, 2019, 18, 382-404.	0.8	1
508	A Paradigm Shift in the Development of Anti-Candida Drugs. Current Topics in Medicinal Chemistry, 2019, 19, 2610-2628.	1.0	1
509	Viral Diseases and Natural Products: Prospects in COVID-19 Treatment (Part-I). Current Pharmaceutical Design, 2020, 26, 5221-5223.	0.9	1
510	Link of COVID-19 and Neurodegenerative Disorders. CNS and Neurological Disorders - Drug Targets, 2022, 21, 208-209.	0.8	1
511	Optimization of antibacterial activity of ethanolic extracts of Eucalyptus tereticornis and Nigella sativa: Response surface Methodology. Pakistan Journal of Pharmaceutical Sciences, 2018, 31, 1259-1266.	0.2	1
512	Crosstalk between SARS-CoV-2 Infection and Type II Diabetes. Combinatorial Chemistry and High Throughput Screening, 2022, 25, 2429-2442.	0.6	1
513	Crosstalk Between SARS-CoV-2 Infection and Neurological Disorders: A Review. CNS and Neurological Disorders - Drug Targets, 2022, 21, .	0.8	1
514	Effect of sevin on kinetic parameters of camel retina acetylcholinesterase. IUBMB Life, 1997, 42, 235-246.	1.5	0
515	Effect of malathion on kinetic parameters of acetylcholinesterase (EC 3.1.1.7) In vitro. IUBMB Life, 1997, 43, 89-97.	1.5	0
516	Editorial (Thematic Issue: Linkage of Neurodegenerative Disorders with Other Health Issues " Volume) Tj ETQq0 0 0 rgBT /Qverlock 10	0.8	0
517	The association of nutritional profile and prognosis of degenerative diseases associated with carbohydrate and lipid metabolism at high altitude of district Ziarat, Pakistan. Saudi Journal of Biological Sciences, 2015, 22, 50-55.	1.8	0
518	Editorial (Thematic Issue: Medicinal Chemistry: Neurological and Endocrinological Disorders). Medicinal Chemistry, 2016, 12, 202-203.	0.7	0
519	Editorial : Thematic Issue (Association of CNS Disorders with Other Health Issues). CNS and Neurological Disorders - Drug Targets, 2016, 15, 1201-1202.	0.8	0
520	Editorial (Thematic Issue: Linkage of CNS and Immunology with Psychology: Searching for New) Tj ETQq0 0 0 rgBT /Qverlock 10 Tf 50 14	0.8	0
521	Characterisation of Bone Beneficial Components from Australian Wallaby Bone. Medicines (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 0	0.7	0
522	EDITORIAL: Current Views on Neurodegeneration: Computational to Clinical Research. Current Topics in Medicinal Chemistry, 2017, 17, 1319-1319.	1.0	0

#	ARTICLE	IF	CITATIONS
523	Editorial: Frontier View on Drug Discoveries for Different Diseases - Volume 3. Current Drug Metabolism, 2017, 18, 784-785.	0.7	0
524	Editorial: Frontier View on Drug Discoveries for Different Diseases - Part II. Current Drug Metabolism, 2017, 18, 88-89.	0.7	0
525	Updates on Neurodegenerative and Metabolic Disorders: Synthetic, Biological and Computational Aspects. Current Medicinal Chemistry, 2019, 25, 5291-5292.	1.2	0
526	Challenges in the Discovery of Novel Therapeutic Agents in Cancer (Part III). Current Drug Metabolism, 2020, 21, 4-5.	0.7	0
527	Current Challenges in Management of Neurological Disorders (Part-I). Current Pharmaceutical Design, 2020, 26, 711-713.	0.9	0
528	Challenges in the Discovery of Novel Therapeutic Agents in Cancer. Current Drug Metabolism, 2020, 20, 931-932.	0.7	0
529	Challenges in the Discovery of Novel Therapeutic Agents in Cancer. Current Drug Metabolism, 2020, 20, 1004-1005.	0.7	0
530	Elucidation of PLK1 Linked Biomarkers in Oesophageal Cancer Cell Lines: A Step Towards Novel Signaling Pathways by p53 and PLK1-Linked Functions Crosstalk. Protein and Peptide Letters, 2021, 28, 340-358.	0.4	0
531	Computational Analysis of Domains Vulnerable to HPV-16 E6 Oncoprotein and Corresponding Hot Spot Residues. Protein and Peptide Letters, 2021, 28, 414-425.	0.4	0
532	Natural Resources for Human Health: A New Interdisciplinary Journal Dedicated to Natural Sciences. , 2021, 1, 1-2.		0
533	Total Stromal Fraction (TSF) - Fortified Adipose tissue-derived Stem Cells Source: An Emerging Regenerative Realm Against COVID-19 Induced Pulmonary Compromise. Coronaviruses, 2021, 02, .	0.2	0
534	Viral Diseases and Natural Products: Prospects in COVID-19 Treatment (Part IV). Current Pharmaceutical Design, 2021, 27, 3501-3501.	0.9	0
535	Viral Diseases and Natural Products: Prospects in COVID-19 Treatment (Part III). Current Pharmaceutical Design, 2021, 27, 3423-3423.	0.9	0
536	Quinoline Derivatives: Candidate Drugs for a Class B G-Protein Coupled Receptor, the Calcitonin Gene-Related Peptide Receptor, a Cause of Migraines. CNS and Neurological Disorders - Drug Targets, 2014, 13, 1130-1139.	0.8	0
537	Influence of Hepatitis B Virus Genetic Heterogeneity on Treatment Response Against Lamivudine and Interferon in Pakistani Isolates. Anti-Infective Agents, 2016, 14, 121-125.	0.1	0
538	Effects of Ascorbic Acid on Tax, NF- κ B and MMP-9 in Human T-cell Lymphotropic Virus Type 1 Positive Malignant T-Lymphocytes. Anti-Cancer Agents in Medicinal Chemistry, 2018, 18, 237-244.	0.9	0
539	Nanotechnology as an emerging pathway for cancer therapy and diagnosis. Current Pharmaceutical Design, 2018, 24, .	0.9	0
540	Challenges in the Discovery of Novel Therapeutic Agents for Cancer Treatment (Part IV). Current Drug Metabolism, 2020, 21, 165-166.	0.7	0

#	ARTICLE	IF	CITATIONS
541	Alzheimer Disease and Sleep Disorders: Insights into the Possible Disease Connections and the Potential Therapeutic Targets (Part II). CNS and Neurological Disorders - Drug Targets, 2021, 20, 674-676.	0.8	0
542	Emergence and Reemergence of Human Coronaviruses: Spike Protein as the Potential Molecular Switch and Pharmaceutical Target. Current Pharmaceutical Design, 2020, 26, 3566-3576.	0.9	0
543	Alzheimer Disease and Sleep Disorders: Insights into the Possible Disease Connections and the Potential Therapeutic Targets (Part I). CNS and Neurological Disorders - Drug Targets, 2021, 20, 572-573.	0.8	0
544	Molecular docking studies of tea (<i>Thea sinensis</i> Linn.) polyphenols inhibition pattern with Rat P-glycoprotein. ChemistrySelect, 2020, .	0.7	0
545	Current Challenges in the Management of Neurological Disorders (Part-II). Current Pharmaceutical Design, 2020, 26, 4687-4689.	0.9	0
546	A Study on Serological Reactivity Profile of Different Antigen Preparations with Bancroftian filariasis Human Infection Sera. Protein and Peptide Letters, 2020, 27, 841-850.	0.4	0
547	Computational Analysis of Dynamical Fluctuations of Oncoprotein E7 (HPV 16) for the Hot Spot Residue Identification Using Elastic Network Model. Letters in Drug Design and Discovery, 2020, 17, 1393-1400.	0.4	0
548	Identification of Putative "Multifunctional Drug" Against Anthrax Toxins via Integrative Computational Approach. Letters in Drug Design and Discovery, 2020, 17, 1516-1530.	0.4	0
549	Current views on Medicinal Chemistry versus Green Chemistry for Management of Broad-spectrum Health Issues. Medicinal Chemistry, 2020, 16, 1005-1006.	0.7	0
550	Prediction of Secondary and Tertiary Structure and Docking of Rb1WT And Rb1R661W Proteins. Current Biotechnology, 2022, 11, 71-85.	0.2	0
551	Estimation and correlation of IC50 for the inhibition of human erythrocyte acetylcholinesterase by cis-diamminediaquaplatinum (II). Anticancer Research, 1997, 17, 4483-6.	0.5	0
552	Current Overview on the Potency of Natural Products for Modulating Myeloid-derived Suppressor Cells Dependent Cold Tumors. Current Medicinal Chemistry, 2022, 29, 6197-6216.	1.2	0
553	Targeting Cellular Signalling Pathways in Cancer by Natural Compounds. Current Medicinal Chemistry, 2021, 28, 7986-7987.	1.2	0
554	Venomous Peptides as Cardiac Ion Channel's Modulators. Venoms and Toxins, 2022, 2, .	0.3	0
555	Viral Diseases and Natural Products: Prospects in COVID-19 Treatment (Part V). Current Pharmaceutical Design, 2022, 28, 947-947.	0.9	0
556	Dietary Alterations in Impaired Mitochondrial Dynamics Due to Neurodegeneration. Frontiers in Aging Neuroscience, 0, 14, .	1.7	0